Study Protocol  AC-078A20 [ADDRESS_258592]-541468 in Elderly Subjects With Insomnia Disorder . 
ClinicalTrials.gov Identifie r [STUDY_ID_REMOVED]  
The study was sponsored was  sponsored by [CONTACT_215197].  
Study sponsorship was transferred to Idorsia Pharmaceuticals Ltd  in July 2018.  
TPL-000052_v11ACT- [ADDRESS_258593] -541468 in elderly subjects with insomnia disorder  
Study Phase:  [ADDRESS_258594] Number:  2016-000827-16  
Status and version:  Final  Version 2 
Date:  [ADDRESS_258595]  2016  
Document type  Amended g lobal protocol  
Actelion document number 
(Doc No.): D-16.[ADDRESS_258596] 2016 , page 2/[ADDRESS_258597] 2016 , page 5/[ADDRESS_258598]  2016 -000827 -16 
Doc No D -16.394 
 
 
INVESTIGATOR SIGNATURE [CONTACT_180549] / number 
ACT -[ADDRESS_258599] -541468 in elderly
 
subjects with insomnia disorder.  
I agree t
o the terms and conditions relating to this study as defined in this protocol, the e lectronic 
Case Report Form (eCRF ), and any other protocol -related do
cuments. I fully understand that any 
changes instituted by [CONTACT_093](s) without previous agreement with the sponsor would 
constitute a protocol deviation, including any ancillary studies or procedures performed on s tudy 
subjects (other than those procedures necessary for the wellbeing of the subjects).  
I agree to co
nduct this study in accordance with the Declaration of Helsinki principles, 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP) gui delines, and 
applicable regulations and laws. I will obtain approval by [CONTACT_215198] (IEC/IRB) prior to study start and signed informed consent from all 
subjects included in this study. If an amendment to the protocol is necessary, I will obtain 
approval by [CONTACT_18369]/IRB and ensure approval by [CONTACT_208179], and I will re
-consent th
e subjects (if 
applicable). I will allow direct access to source documents and study facilities to sponsor representative(s), particularly Clinical Research Associate(s) (CRA[s]) and auditor(s), and agree to inspection by [CONTACT_208180]/IRB representative(s). I will ensure that the study 
treatment(s) supplied by [CONTACT_208181]/are being used only as described in this protocol. I will 
ensure that all subjects have understood the nature, objectives, benefits, implications, risks and inconveniences for participating in this study. During the conduct of the study, I will constantly 
monitor the risk/benefit balance for an individual subject. I confirm herewith that the sponsor is 
allowed to enter and utilize my professional contact [CONTACT_215199]. 
 Country  Site number  Town  Date   Signature  
[INVESTIGATOR_97159]        
[INVESTIGATOR_215152] -[ADDRESS_258600] 2016 , page 6/[ADDRESS_258601] OF ABBREVIATION S AND ACRONYMS  ..........................................................13  
SUBSTANTIAL GLOBAL A MENDMENT 1  .................................................................16  
PROTOCOL SYNOPSIS AC -078A202 ............................................................................ 20 
PROTOCOL  ......................................................................................................................34  
1 BACKGROUND  .........................................................................................................34  
1.1 Insomnia disorder .........................................................................................34  
 Definition  ..........................................................................................34  1.1.1
 Epi[INVESTIGATOR_623] ....................................................................................34  1.1.2
 Treatments  ........................................................................................35  1.1.3
 Unmet medical need  .........................................................................37  1.1.4
1.2 Study treatment: ACT -[ADDRESS_258602] -541468 properties .................................................................... 38 1.2.2
[IP_ADDRESS]  Nonclinical data  .......................................................................38  
[IP_ADDRESS]  Clinical studies  ........................................................................[ADDRESS_258603] 2016 , page 7/[ADDRESS_258604]  2016 -000827 -16 
Doc No D -16.394 
 
 
3 OVERALL STUDY DESIGN AND PLAN  ...............................................................47  
3.1 Study design .................................................................................................47  
 Study phases  .....................................................................................48  3.1.1
[IP_ADDRESS]  Screening phase  .......................................................................48  
[IP_ADDRESS]  Double -blind treatment phase  ................................................. 48 
 Study duration ...................................................................................49  3.1.2
3.2 Study design rationale ..................................................................................49  
3.3 Site staff and their roles: polysomnography technologists ...........................[ADDRESS_258605] population description .....................................................................51  
4.2 Rationale for the selection of the study population . .....................................51  
4.3 Inclusion criteria  ...........................................................................................52  
4.4 Exclusion criteria  ..........................................................................................53  
5 TREATMENTS  ..........................................................................................................54  
5.1 Study treatment  .............................................................................................54  
 Investigational treatment and matching placebo: description 5.1.1
and rationale  ......................................................................................55  
 Study treatment administration during the different study 5.1.2
phases  ................................................................................................55  
[IP_ADDRESS]  Screening phase  .......................................................................55  
[IP_ADDRESS]  Double -blind treatment phase  ................................................. 55 
 Treatment assignment  .......................................................................56  5.1.3
 Blinding ............................................................................................56  5.1.4
[IP_ADDRESS]  Screening phase  .......................................................................56  
[IP_ADDRESS]  Double -blind treatment phase  ................................................. 57 
 Unblinding ........................................................................................57  5.1.5
[IP_ADDRESS]  Unblinding for final analyses ..................................................57  
[IP_ADDRESS]  Unblinding for IDMC review ..................................................57  
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse 
reaction  ....................................................................................57  
[IP_ADDRESS]  Emergency procedu re for unblinding ......................................57  
 Study treatment supply .....................................................................58  5.1.6
[IP_ADDRESS]  Study t reatment packaging and labeling  .................................58  
[IP_ADDRESS]  Study treatment distribution and storage .................................58  
[IP_ADDRESS]  Study treatment dispensing .....................................................58  
[IP_ADDRESS]  Study treatment return and destruction ...................................[ADDRESS_258606] 2016 , page 8/[ADDRESS_258607]  2016 -000827 -16 
Doc No D -16.394 
 
 
 Study treatment accountability and compliance with study 5.1.7
treatment  ...........................................................................................59  
[IP_ADDRESS]  Study treatme nt accountability ................................................59  
[IP_ADDRESS]  Study treatment periods compliance .......................................59  
 Study treatment dose adjustments and interruptions ........................60  5.1.8
 Premature discontinuation of double -blind study treatment  ............. 60 5.1.9
5.2 Previous and concomitant therapy ................................................................61  
 Definitions  ........................................................................................61  5.2.1
 Reporting of previous/concomitant therapy in the eCRF .................61  5.2.2
 Allowed concomitant therapy ...........................................................61  5.2.3
 Forbidden concomitant therapy ........................................................61  5.2.4
 Forbidden concomitant diet and activities  ........................................62  5.2.5
6 STUDY ENDPOINTS  ................................................................................................62  
6.1 Efficacy endpoints ........................................................................................62  
 Primary efficacy endpoint  .................................................................62  6.1.1
 Secondary efficacy endpoint .............................................................63  6.1.2
 Other efficacy endpoints ...................................................................63  6.1.3
6.2 Safety endpoints  ...........................................................................................64  
6.3 Pharmacokinetic endpoints ...........................................................................65  
7 VISIT SCHEDULE AND STUDY ASSESSMENTS  ................................................65  
7.1 Study visits  ...................................................................................................65  
 Screening/re -screening  ...................................................................... 65 7.1.1
 Unscheduled visits ............................................................................65  7.1.2
7.2 Study assessments  .........................................................................................69  
 Demographics ...................................................................................71  7.2.1
 Insomnia severity index ..................................................................71  7.2.2
 Efficacy assessments  .........................................................................71  7.2.3
[IP_ADDRESS]  Polysomnography ....................................................................71  
[IP_ADDRESS]  Sleep diary  ...............................................................................73  
 Safety assessments  ............................................................................73  7.2.4
[IP_ADDRESS]  Weight and height ...................................................................73  
[IP_ADDRESS]  Vital signs  ................................................................................74  
[IP_ADDRESS]  Physical examination  ...............................................................74  
[IP_ADDRESS]  Digit Symbol Substitution Test .............................................75  
[IP_ADDRESS]  Sheehan Disability Scale .......................................................75  
[IP_ADDRESS]  Karolinska Sleepi[INVESTIGATOR_7110]  ....................................................75  
[IP_ADDRESS]  Columbia Suicide Severity Rating Scale ..............................75  
[IP_ADDRESS]  Neurological examinations  ......................................................[ADDRESS_258608] 2016 , page 9/[ADDRESS_258609]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS]  ECG assessment  ......................................................................76  
 Laboratory assessments  ....................................................................77  7.2.5
[IP_ADDRESS]  Type of laboratory ...................................................................77  
[IP_ADDRESS]  Laboratory tests  .......................................................................[ADDRESS_258610] -STUDY TREATMENT / ME DICAL 
CARE  .......................................................................................................................... 79 
8.1 Study completion as per protocol .................................................................79  
8.2 Premature withdrawal fr om study ................................................................79  
8.3 Premature termination or suspension of the study ........................................80  
8.4 Medical care of subjects after study completion / withdrawal from 
study ..............................................................................................................[ADDRESS_258611] 2016 , page 10/[ADDRESS_258612]  2016 -000827 -16 
Doc No D -16.394 
 
 
 Primary efficacy variable  ..................................................................87  10.2.1
[IP_ADDRESS]  Missing values .........................................................................88  
 Secondary efficacy variable ..............................................................88  10.2.2
[IP_ADDRESS]  Missing values .........................................................................88  
 Other exploratory efficacy variables  .................................................88  10.2.3
[IP_ADDRESS]  Sleep -maintenance endpoint .................................................... 88 
[IP_ADDRESS]  Sleep -initiation endpoint ......................................................... 89 
[IP_ADDRESS]  Total sleep time endpoint ........................................................89  
[IP_ADDRESS]  SQ ............................................................................................89  
[IP_ADDRESS]  Sleep architecture  ....................................................................89  
[IP_ADDRESS]  Sleep continuity .......................................................................89  
[IP_ADDRESS]  SE ............................................................................................89  
[IP_ADDRESS]  Next -day performance ............................................................. 90 
 Safety variables  .................................................................................90  10.2.4
[IP_ADDRESS]  Adverse events  ........................................................................90  
[IP_ADDRESS]  Laboratory data  ........................................................................90  
[IP_ADDRESS]  ECG  .........................................................................................90  
[IP_ADDRESS]  Other safety parameters of interest  ..........................................90  
[IP_ADDRESS]  Vital signs  ................................................................................91  
[IP_ADDRESS]  Body weight ............................................................................91  
 Other variables  ..................................................................................91  10.2.5
10.3  Description of statistical analyses  .................................................................91  
 Overall testing strategy  .....................................................................91  10.3.1
 Analysis of the primary efficacy variable  .........................................91  10.3.2
[IP_ADDRESS]  Hypotheses and statistical model ............................................91  
[IP_ADDRESS]  Handling of missing data  .........................................................92  
[IP_ADDRESS]  Main analysis  ...........................................................................92  
[IP_ADDRESS]  Supportive/sensitivity analyses ...............................................93  
 Analysis of secondary efficacy variable  ...........................................94  10.3.3
 Analysis of other exploratory efficacy variables ..............................94  10.3.4
[IP_ADDRESS]  Subgroup a nalyses  ...................................................................94  
 Analysis of the safety variables  ........................................................94  10.3.5
[IP_ADDRESS]  Analysis of safety and tolerability endpoints ..........................94  
[IP_ADDRESS]  Adverse events  ........................................................................94  
[IP_ADDRESS]  Laboratory variables  ................................................................95  
[IP_ADDRESS]  ECG  .........................................................................................95  
[IP_ADDRESS]  Vital signs  ................................................................................95  
[IP_ADDRESS]  Other safety parameters of interest  ..........................................95  
[IP_ADDRESS]  Exposure -safety analysis  ......................................................... 96 
[IP_ADDRESS]  Pharmacokinetic  ......................................................................[ADDRESS_258613] 2016 , page 11/[ADDRESS_258614]  2016 -000827 -16 
Doc No D -16.394 
 
 
10.4  Interim analyses  ............................................................................................96  
10.5  Sample size  ...................................................................................................96  
11 DATA HANDLING  ....................................................................................................97  
11.1  Data collection  ..............................................................................................97  
11.2  Maintenance of data confidentiality  .............................................................98  
11.3  Database management and quality control  ...................................................98  
12 PROCEDURES AND GOOD CLINICAL PRACTICE  .............................................99  
12.1  Ethics and Good Clinical Practice  ................................................................99  
12.2  Independent Ethics Committee / Institutional Review Board  ......................99  
12.3  Informed consent ..........................................................................................99  
12.4  Compensation to subjects and investigators ...............................................100  
12.5  Protocol adherence/compliance  ..................................................................[ADDRESS_258615] 2016 , page 12/[ADDRESS_258616] ....................................................121  
Appendix 6  Insomnia Severity Index ...............................................................122  
Appendix 7  Sheehan Disability Scale ..............................................................[ADDRESS_258617] 2016 , page 13/[ADDRESS_258618] OF ABBREVIATIONS AND ACRONYMS 
AASM   American Academy of Sleep Medicine  
AE  Adverse event  
AHI  Apnea/hypopnea index 
ALT   Alanine aminotransferase  
AST   Aspartate aminotransferase 
AUC   Area under t
he plasma concentration -time curve  
AUC 0-∞  Area under the plasma concentration -time curve f rom zero to 
infinity  
BCRP   Breast C
ancer Resistance Protein  
BMI   Body mass index 
BP  Blood pressure 
bpm  Beats per minute  
CBT   Cognitive behavioral therapy  
Cmax  Maximum plasma concentration  
CNS   Central nervous system 
CR  Controlled -release  
CRA   Clinical R
esearch Associate  
CRO   Contract research organization  
CSR   Clinical Study Report  
C-SSRS©  Columbia Su icide Severity Rating Scale  
CYP   Cytochrome P450 
DDI  Drug -drug i nteract
ion 
DoA  Deleg
ation of Authority 
DORA  Dual orexin receptor antagonist 
DSM   Diagnostic and Statistical Manual of Mental Disorders  
DSST  Digit Symbol Substitution Test 
ECG   Electrocardiogram  
eCRF   Case Report Form (eCRF,  electronic CRF)  
EMA   European Medicines Agency  
Emax  Effect maximum  
EOS   End of Study 
ACT -[ADDRESS_258619] 2016 , page 14/[ADDRESS_258620]  2016 -000827 -16 
Doc No D -16.394 
 
 
EOT   End of Treatment 
FAS  Full Analysis Set 
FDA   Food and Drug Administration 
GABA   Gamma -aminobutyric acid  
GCP   Good Clinical Practice  
HR  Heart rate  
IB  Investigator’ s Brochure  
ICF  Informed Consent Form 
ICH  International Council for Harmonisation  
IDMC   Independent Data Monitoring Committee 
IEC   Independent ethics committee 
IRB  Institutional review board  
IRT  Interactive Response Technology  
ISAC   Independent statistical analysis center  
ISB   Independent Safety Board  
ISF  Investigator Site File  
ISI  Insomnia Severity Index 
KSS  Karolinska Sleepi[INVESTIGATOR_215153] -Mod  Multiple C omparison Procedure – Modeling 
MCT   Multiple contrast test 
MedDRA   Medical Dictionary for Regulatory Activities  
mFAS   Modified Full Analysis Set  
NOAEL   No-observed -adverse -effect level  
NOEL   No-observed -effect lev
el 
OTC   Over -the-counter 
PD  Pharmacody
namics  
P-gP  P-glycoprotein [ADDRESS_258621] 2016 , page 15/[ADDRESS_258622]  2016 -000827 -16 
Doc No D -16.394 
PSG Poly somnography 
QS Qua
lity System 
QT C Corrected QT interval  
REM  Rapid eye movement  
RSI Reference safety information  
SAD
 Single -ascending dos
e 
SAE  Seri ous ad
verse event  
SAP Statis
tical analysis plan  
SDS© Sheehan Disability Scale  
SE Sleep efficiency  
SIV Site initiation visit  
sLS
O Sub
jective latency to sleep onset 
sNA Self-reported number
 of awakenings 
SOC  Sys tem or
gan class  
SOP Standard operating procedure  
SpO [ADDRESS_258623] 2016 , page 16/[ADDRESS_258624] 2016 , page 17/[ADDRESS_258625] 2016 , page 18/[ADDRESS_258626] 2016 , page 19/[ADDRESS_258627] 2016 , page 20/[ADDRESS_258628] -541468 on the chang e of wake after 
sleep o nset (WASO) assessed by [CONTACT_25899] (PSG) on 
the first two days of each treatment period.  
Secondary objective  
The secondary objective of th e study is to evaluate the 
dose response of ACT -541468 on latency to  persistent s leep 
(LPS) on the first two days of each treatment period.  
Other objectives  
Other objectives are described in S ection  2.3.  
DESIGN  Multi -center, double -blind, randomized, placebo -controlled, 
5-period, [ADDRESS_258629] randomization. 
It includes the screening period (from Day −28 to Day − 7) and 
the run -in period (from
 Day − 14 to Day − 1).  
The screening period  starts with Visit (V) 1, which occurs 
between Day − 28 and Day − 14. V1  is followed by [CONTACT_215200] d iary for at least 
7 consecutive days at home and until V2.  
The run-in perio d occurs between Day − 14 and Day − 1 and 
starts with V2. V2 consists of two consecutive PSG nights on 
single -blind placebo treatment  occurring be tween Day − 14 and 
Day −6. V2 is followed by [ADDRESS_258630] 2016 , page 21/[ADDRESS_258631] evening of  the 
Random
ization visit (V3) and ends in the second morning of 
V7. It consi sts of five  treatment periods , each consisting of 
two consecutive PSG nights on the assigned study treatment  
followed by a 5 - to 12 -day washout . 
The End of Treatment (EOT) is reached in the second 
morning of V7, after the last dose of double -blind treatment 
and after all morning assessments have been performed. 
The safety f ollow- up phase  starts after EOT and lasts at least 
30 days  (i.e., until the second follow -up telepho
ne call) . A first 
telephone call is done 5 days ( +7 days) after EOT to collect 
treatment -emergent ad
verse events (TE AEs) from last study 
treatment dose.  
The End of Study  (EOS) for a single subject is defined as the 
date of the [ADDRESS_258632] is 
expected to be approximately 16 weeks (see diagram below).  
 
V = visit; ▬ polysomnographic (PSG) nights ; D = dose; P = placebo . 

ACT -[ADDRESS_258633] 2016 , page 22/[ADDRESS_258634] visit.  
SITE(S)  
/ COUNTRY(IES)  Approximately 10 sites in two countries (US, G ermany ). 
SUBJECTS /SEQUENCE
S Approximately 50 subjects will be centrally randomized to five 
different sequences of five study treatments according to a 
Latin square design. 
INCLUSION CRITERIA  1. Signed informed consent prior to any study -mandated 
procedure (V1). 
2. Male or female aged ≥  65 years (V1).  
3. Body  mass index (BMI): 18.5 ≤  BMI (kg/m2) < 32.0 (V1). 
4. Insomnia d
isorder according to Diagnostic and Statistical 
Manual of Mental Disorders -5 criteria
 (V1).  
5. Self-reported history of all of the following on at least 
[ADDRESS_258635] 3 months prior to V1: 
• ≥ 30 minutes to fall asleep  
• Wake time during sleep ≥ 30 minutes 
• Total sleep time ( TST) of ≤  6.5 h  
6. Insomnia Severity Index ( ISI) score greater than or equal 
to 15 (V1).  
7. Willing to comply with all aspects of the study protocol 
(V1).  
8. Ability to communicate well with the investigator, to 
understand the study requirements and judged by [CONTACT_215201], place, time 
and situation (V1).  
9. Meeting  the following sleep parameters on at least 3 nights 
out of 7 consecutive nights on the sleep diary completed at home between V1 and V2 (to be checked at V2):  
• ≥ 30 minutes to fall asleep  
• Wake time during sleep ≥ 30 minutes  
• TST of ≤ 6.[ADDRESS_258636] 2016 , page 23/[ADDRESS_258637]  2016 -000827 -16 
Doc No D -16.394 
 
 
10. Usual  bedtime between 21:30 and 00:30 as reported on the 
sleep diar y completed at home between V1 and V2 (to be 
checked at V2).  
11. Regular  time in bed between 6 and 9 hours as reported on 
the sleep diary completed at home between V1 and V2 (to 
be checked at V2).  
12. Meeting  the following sleep parameters on the two PSG 
nights (V 2): 
• Mean  LPS ≥ 20 minutes  (with neither of the two nights 
< 15 minutes ), and 
• Mean  WASO ≥ 30 minutes  (with neither of the two 
nights <  20 minutes ), and 
• Mean  TST < 420 minutes . 
EXCLUSION CRITERIA  1. Any current sleep disorder(s) other than insomnia , or any 
lifetime history of related breathing disorder, periodic limb 
movement disorder, restless legs syndrome, circadian 
rhythm disorder, rapid eye movement ( REM ) behavior 
disorder, or narcolepsy (V1). 
2. Self-reported usual daytime nappi[INVESTIGATOR_007] ≥  1 hour per day, and  
on ≥ 3 days per week (V1).  
3. Caffeine
 consumption ≥ 600 mg per day (V1)  [see 
Appendix 3 ]. 
4. Shift work within 2 weeks prior to the screening visit, or 
planned shift work during study (V1).  
5. Travel ≥ three  time zones within 1 week prior to the 
screening  visit, or planned travel ≥  three time zones during 
study (V1).  
6. Hematology  or biochemistry test results deviating from 
the normal range to a clinically relevant  extent as per 
judgment of the investigator (V1, V2)  
7. Aspartate aminotransferase and/or alanine 
aminotransferase > 2 × the upper limit of n ormal (ULN) 
and/or  direct  bilirubin > 1.5 × ULN ( V1, V2).  
ACT -[ADDRESS_258638] 2016 , page 24/[ADDRESS_258639]  2016 -000827 -16 
Doc No D -16.394 
 
 
8. Severe renal impairment: known or defined as estimated 
creatinine clearance < 30 mL/min, according to the 
4-variable M odificat ion of Diet in R enal Disease  formula 
(V1, V2). 
9. Unstable medical condition, significant medical disorder 
or acute illness within [ADDRESS_258640] ’s safety or interfere with the study assessments 
(V1).  
10. Systolic blood pressure (BP) >  150 mmHg and diastolic 
BP > 90 mmHg (V1,V2). 
11. Resting  pulse rate <  50 or ≥  100 beats per minute (V1,  
V2). 
12. Any of the following conditions related to corrected QT 
(QTc) intervals (V1,V2):  
• A prolonged QTc interval (QTc  greater than 450 ms). 
In case of QTc greater than [ADDRESS_258641] 
electrocardiogram ( ECG ), a second ECG recording will 
be performed after at least [ADDRESS_258642] is not eligib le.  
• A history of additional risk factors for torsade de 
pointes (e.g., heart failure, hypokalemia, fami ly history 
of long QT syndrome). 
13. Any of the following conditions related to suicidality:  
• Any suicidal ideation with intent with or without a plan 
at scr eening , i.e., answering “ Yes” to questions 4 or 
5 on the suicidal i deation section of the 
screening / baseline version of the Columbia -Suicide 
Sev
erity Rating Scale ( C-SSRS;V1, V2). 
• Lifetime history of suicide attempt (V1).  
14. Any known factor or disease tha t might interfere with 
treatment compliance, study conduct or interpretation of 
the results such as history of non -compliance to medical 
ACT -[ADDRESS_258643] 2016 , page 25/[ADDRESS_258644] sleep, motor performance, or cognition, 
including Parkinson disease, predementia, dementia, other 
neurodegenerative disorders, and stroke, (V1).  
15. Treatment with another investigational drug within 
1 month prior to V1. 
16. Known  hypersensitivity or contraindication to drugs of the 
same class of the study treatment or to any excipi[INVESTIGATOR_215154] (V1). 
17. Treatment  with prohibited central nervous system 
(CNS )- active drugs [ as def ined in Appendix 4 ] for 
5 half-lives of the respective drug (but at least 2 weeks) 
prior to V1 and until 24 hours after EOT, including 
over-the-counter (OTC) medicati on and herbal medicines.  
18. Cognitive  behavioral therapy  (CBT)  within one month 
prior to V1.  
19. Treatment with modera te to strong cytochrome P450 
(CYP ) 3A4 inhibitors , CYP3A4  inducers, sensitive 
CYP3A4 substrates, P -glycoprotein 1
 (P-gP) substrates,
 
Breast Cancer Resistance Protein  (BCRP ) substrates  and 
CYP2B6 substrates  [as defined in Appendix 4]  within 
[ADDRESS_258645] 3 consecutive days (V1).  
22. Positive  drug test (for benzodiazepi[INVESTIGATOR_1651], barbiturates, 
cannabinoids, opi[INVESTIGATOR_858], amphetamines, or cocaine) or 
presence of alcohol in exhaled breath as detected by 
[CONTACT_215202] (V1, V2). 
23. Heavy tobacco use ( ≥ 10 cigarettes per day) and/or 
inability  to refrain from smoking for at least 14 hours 
during the night (V1).  
ACT -[ADDRESS_258646] 2016 , page 26/[ADDRESS_258647]  2016 -000827 -16 
Doc No D -16.394 
 
 
24. Apnea /hypopnea index ≥ 15/h on the first PSG screening 
night according to the American Academy of Sleep 
Medicine (AASM) criteria (V2).  
25. Apnea or hypopnea event (according  to AASM criteria ) 
associated  with oxygen saturation by [CONTACT_406] 
< 80%, on the first PSG screening night (V2). 
26. Periodic limb movement with arousal index ≥  15/h on the 
first PSG screening night (V2).  
STUDY TREATMENTS Investigational treatment  
ACT -[ADDRESS_258648] -541468 doses will include: [ADDRESS_258649] two evenings of the 
assigned treatment period and in addition at V2. 
Number of capsules taken according to treatment dose 
 Placebo 
(0) 5 10 25 
Placebo (0)  2 0 0 0 
5 1 1 0 0 
10 1 0 1 0 
25 1 0 0 1 
50 0 0 0 2 
 
CONCOMITANT 
THERAPY 
(MEDICATION, DIET, ACTIVITIES)  The following therapi[INVESTIGATOR_215155]:  
• Treatment with another investigational drug until the end of 
the safety follow -up phase.  
• Prohibited CNS -active medications, including OTC and 
herbal medicines, until 24 hours after EOT [see 
Appendix 4].  
• Treatment with moderate to strong  CYP3A4 inhibitors , 
CYP3A4  inducers , sensitive CYP3A4 substrates  (i.e., have Treatment  
dose (mg)  Dose strength  
(mg)  
ACT -[ADDRESS_258650] 2016 , page 27/[ADDRESS_258651]) , P-gP 
substrates, BCRP substrates , and CYP2B6 substrates  
[see Appendix 4]  until 24 hours after EOT . 
• CBT and other psychological therapi[INVESTIGATOR_014], excluding common 
advice related to sleep hygiene, until 24 hours after EOT.   
The following activities and diet are forbidden during the 
study:  
• Consumption of grapefrui t and grapefruit juice until 
24 hours after EOT.  
• Consumption of food within 2 hours prior to study 
treatment intake.  
• Caffeine consumption [more details in Appendix 3] 
– > 600 mg/day 
– after 14:00 on the days of PSG nights 
• Alcohol consumption [more details in Appendix 2]:  
– > 2 drinks a day 
– within 24 hours prior to PSG night and during all PSG visits  
• Heavy tobacco use ( ≥ 10 cigarettes per day) and smoking 
during PSG assessment at night. At home, it is 
recommended not to smoke or to use other tobacco 
products including oral s nuff tobacco from 10 pm to 8 am. 
ENDPOINTS Primary efficacy endpoint(s)  
The primary efficacy endpoint of this study is defined as the change of WASO from Baseline
1 to Days 1 and 22 as 
determined by [CONTACT_63175].  
WASO is the time (min utes) spent awake after onset of 
persistent sleep (see definition of LPS below ) until lights on as 
determined by [CONTACT_63175].  
Total time in bed is fixed at 480 min utes (8 hours) during the 
PSG nights. The first screening PSG recording starts (lights 
off) within ± 30 minutes of usual bedtime (determined by [CONTACT_215203] V1 and V2); this time is then considered as the 
                                                 
1 ‘Baseline’ is the mean of the two  PSG nights during run -in period (V2).  
2 ‘Days 1 and 2’ are the mean of the corresponding two PSG treatment nights  for a given treatment period.  
ACT -[ADDRESS_258652] 2016 , page 28/[ADDRESS_258653]  2016 -000827 -16 
Doc No D -16.394 
 
 
habitual bedtime and held constant ±  5 min throughout the 
study.  PSG is recorded for 960 epochs of 30 seconds (8 hours) 
from lights off until lights o n. PSG recording is centrally 
scored by [CONTACT_215204]. 
Secondary efficacy endpoints  
The secondary efficacy endpoint of this study is defined as the 
change from Baseline1 to Days 1 and 22 in mean LPS.  
LPS is the time (min utes) from start of recordin g to the 
beginning of the first continuous 20 epochs (i.e., 10 minutes ) 
scored as non -wake, i.e., e
pochs scored  as either  sleep  stage  
1 (S1), sleep  stage 2 (S2), sleep  stage  3 (slow -wave s leep)  or
 
REM,  as determined  by [CONTACT_63175].  
Other efficacy endpoints  
Other efficacy endpoints are described in Section 6.1.3. 
Safety endpoints  
• TEAEs3 up to 5 days after study treatment discontinuation.  
• Serious adverse events (S AEs) up to 30 days after study 
treatment discontinuation.  
• Adverse even
ts (AEs) leading to premature discontinuation 
of the double -blind study tr
eatment.  
• AEs of special interest starting or worsening after the first 
dose of the first treatment period until EOS (and after 
adjudication by [CONTACT_42892]): 
– Narcolepsy -like events ( e.g., excessi ve daytime 
sleepi[INVESTIGATOR_008], cataplexy)  
– Complex sleep behavior events. 
– Suicidal thoughts and/or behaviors. 
• Change from Baseline (mean of the first and second 
morning values  after the two PSG nights at V2, run -in 
period) to
 Days 1  and 24 of each period in vital s igns 
(systolic and diastolic BP, pulse rate and body 
                                                 
[ADDRESS_258654] 2016 , page 29/[ADDRESS_258655]  2016 -000827 -16 
Doc No D -16.394 
 
 
temperature).  
• Change from Baseline ( V1) to the second  morning after the 
PSG nights at V7 in body weight. 
• Treatment -emergent EC G abnormalities  from V3 until 
EOT . 
• Change from Baseline ( V2, second  morning) to the second  
morning after the PSG nights at V3, V4, V5, V6 and V7 in 
ECG parameters.  
• Marked laboratory abnormalities on double -blind study 
treatment.  
• Change from Baseline ( V2, second  morning) to the second  
morning after the PSG nights at V3, V4, V5, V6  and V7 in 
laboratory variables. 
• Change fr
om Baseline (mean of the two PSG nights at V2, 
run-in period) to Da
ys 1 and 24 of each treatment period in: 
– Digit Symbol Substitution Test performed in the 
morning, 30–60 minutes after lights on. 
– Sheehan  Disabilit y Scale performed in the morning, 
30–60 minutes after lights on. 
– Karolinska Sleepi[INVESTIGATOR_215156], 
30–60 minutes after lights on. 
• Incidence of most severe suicidal id eation and suicidal 
behavior according to the C -SSRS for each treatm ent 
group. 
Pharmacokinetic  endpoints  
Concentratio n of ACT -541468 (and possibly several of its 
metabolites) approximately 9 –[ADDRESS_258656] 2016 , page 30/[ADDRESS_258657]  2016 -000827 -16 
Doc No D -16.394 
 
 
Full Analysis Set  
The Full Analysis Set (FAS) includes all subjects from the 
Randomized Analysis Se t who received any dose of study 
treatment.  
Modified FAS 
The m odified FAS (mFAS ) includes all patients from the FAS 
and who have at least one WASO assessment at Baseline and at least one at Days 1 and 2 of any given treatment period. 
Per-protocol Analysis Set  
The Per -protocol Analysis Set comprises all subjects from the 
mFAS, who hav e two
 consecutive WASO values at b oth 
Baseline and Days 1 and 2 of each treatment period, and who 
complied with the protocol sufficiently to allow relevant 
assessment of treatment effects.  
Safety Set  
The Safety Set (SS) includes all randomized subjects who 
received at least one dose of study treatment. Subjects will be 
evaluated according to the actual dose they received, which 
may differ from the randomly assigned dose. 
PK Analysis Set The PK Analysis Set includes all subjects in the SS who have at least o ne PK sample collected after initiation of study drug.  
Methods  
The study is intended to select the dose that allows a clinically meaningful reduction of WASO compared to placebo. 
Primary efficacy analysis 
The primary statistical analysis will be performed on the 
mFAS.  
The study is using the generalized  Multiple Comparison 
Procedure – Modeling ( MCP -Mod) approach [Bretz 2005, 
Pi[INVESTIGATOR_17872] 2006, Pi[INVESTIGATOR_17872] 2014] , which combines a  
multiple -comparison pr
ocedure to assess the efficacy of the 
drug versus placebo and a modeling step to further identify the 
dose that is most likely to provide the expected level of 
efficacy (based on the primary efficacy endpoint). The 
generalized approach is appr opriate for this study design where 
ACT -[ADDRESS_258658] 2016 , page 31/[ADDRESS_258659]  2016 -000827 -16 
Doc No D -16.394 
 
 
each patient receives different doses in a sequence. A 
univariate dose-response re lationship is modeled based on the 
mean change from baseline in WASO at each dose. 
The following pre -defined dose -response models are 
considered: one linear, and three E max models. The analysis 
will be performed using the R -package Dose Finding . A 
dose-response relationship is demonstrated if at least one of the 
four multiple c
ontrast tests has an adjusted p -value < 0.05. The 
be
st fitting mod el based on Akaike ’s Information Criterion will 
be used to estimate the target dose, defined as the dose that 
achieves a placebo -corrected m ean reduction from baseline of 
at least 15 min utes with a 95% confidence interval  excluding 0. 
The primary endpoint will be summarized by [CONTACT_215205], median, standard deviation, standard error, quartiles, 
minimum, maximum and 95% confidence limits of mean.  
Secondary  efficacy analysis 
Similarly, 
an MCP -Mod -based anal
ysis will be conducted on 
the secondary endpoint. 
Treatment effect s on the secondary efficacy endpoint will also 
be assessed using a mixed model similar as for the primary 
analysis  
Safety analysis 
Safety analyses will be performed on the SS.  Observations 
(e.g. AEs, laboratory data) occurring within a treatment period 
(from the time of dosing to the time immediately prior to the 
next dose) will be assigned to the dose taken in that period. 
Adverse events:  AEs and SAEs in subjects who were scre ened 
but not part of the SS will be listed.  
The number and percentage of subjects experiencing TEAEs 
and SAEs will be tabulated by [CONTACT_215206]: 
• MedDRA  system organ class (SOC) in alphabetical order 
and individual preferred term within each SOC, in 
descending order of incidence in the highest dose group. 
• Frequency of subjects with events coded with the same 
preferred term, in descending order of incidenc e in the 
ACT -[ADDRESS_258660] 2016 , page 32/[ADDRESS_258661] day of  
double -blind study
 treatment will also be summarized.  
Listings will be provided for all reported AEs, including SAEs. 
In addition, separate listings will be provided f or SAEs, for 
AEs leading to premature discontinuation of study treatment, 
and for AEs with outcome death. 
Laboratory variables:  Descriptive summary statistics by [CONTACT_215207], in both hematolo gy and blood chemistry 
laboratory tests. All central laboratory data will be taken into 
account regardless of whether they correspond to scheduled or unscheduled assessments. Local laboratory results will only be listed and not included in the safety analy
sis. Marked 
laboratory abnormalities will be summarized for each 
laboratory variable by [CONTACT_215208].  
The number and percentage of subjects with 
treatment -emergent laboratory abnormalities will be tabulated 
by [CONTACT_2715]. 
Other e ndpoints  analysis 
Treatment effects on other endpoints will be evaluated and 
described in detail in the statistical analysis plan . 
STUDY COMMITTEES  An Independent Data Monitoring Committee (IDMC) will 
monitor safety and efficacy data in an unblinded manner and 
make appropriate recommendations to ensure safety of the 
subjects, thus ensuring that the study is being conducted with 
the highest scientific and ethical standards. The IDMC will be 
fully operational prior to enrol lment of the first subject in to the 
study. The composition and operation of the IDMC is 
ACT -[ADDRESS_258662] 2016 , page 33/[ADDRESS_258663] , i.e., narcolepsy -like events (e.g., excessive 
daytime sleepi[INVESTIGATOR_008], cataplexy), complex sleep behavior events 
and suicidal thoughts and/or behaviors . The composition and 
operation of the ISB is described in the ISB charter.  
 
ACT -[ADDRESS_258664] 2016 , page 34/[ADDRESS_258665]  2016 -000827 -16 
Doc No D -16.394 
 
 
 PROTOCOL 
1 BACKGROUND 
1.1 Insomnia disorder 
 Definition  1.1.1
The definition of insomnia disorder used in the protocol is the one described in the 
Diagnostic and Statistical Man
ual of Mental Disorders (DSM) [ DSM -5 2013 ]: 
“Insomnia disorder is a dissatisfaction with sleep quantity or quality, associated with 
difficulty initiating or maintaining s
leep, or early morning awakening. Furthermore, the 
sleep disturbance is associated with significant social or functional distress or impairment. Sleep difficulty occurs at least [ADDRESS_258666] 
3 months, and occurs despi[INVESTIGATOR_42842]. The insomnia (a) is not 
better explained by, and does not occur exclusively during the course of another sleep -wake disorder, (b) it is not attributable to the physiological effect of a substance, 
and (c) is not explained by [CONTACT_3252] -existing mental disorders or medical conditions.”  
 Epid emiology 1.1.[ADDRESS_258667] that insomnia symptoms (difficulties initiating sleep, 
early morning awakenings, and  dissatisfaction with sleep) increase with age  
[Ohayon 2001 ]. However, the decrease in ability to sleep is associated with factors 
associated with aging, su ch as depressed mood, respi[INVESTIGATOR_1856], poor perceived 
health and physical disability, not with age per se. A  stagnation or decline in insomnia 
disorder diagnosis in age groups ≥  65 years is seen, as the negative consequences of 
insomnia symptoms on functioning and well -being are likely less endorsed in the elderly 
than in adults  [Ancoli -Israel 2009 , Ohayon 2009 ]. Prevalence of insomnia disorder in 
elderly populations ≥  65 years based on DSM -IV criteria  in Europe was estimated at 
approximately 8% [Ohayon  2010, Ohayon 2002, Schlack 2013]. Insomnia in the elderly 
is twice as common  Lopez -Torres Hidalgo 2012 ]. 
Changes in sleep architecture, such as s low-wave sleep decreases, as well changes in 
sleep parameters such as increase in sleep onset latency and decreases in sleep  
maintenance and efficiency have been described in elderly people. Those changes are 
associated with age, occur in middle age and stabilize from 60 years onwards. Only sleep 
efficiency continues to decline with age [ Ohayo n 2004].  
The co -morbidities associated with insomnia in the elderly  have been examined in a 
number of studies  [Ohayon 2005, Dam 2008, Blackwell 2006]. Elderly individuals with 
insomnia symptoms ha ve poor physic
al and mental health, as well as an increased risk of 
ACT -[ADDRESS_258668] 2016 , page 35/[ADDRESS_258669] in older women . Disrupted sleep in the elderly result s in reduced 
physical performance and impairment in cognitive functioning . Insomnia in elderly 
subjects may also precipi[INVESTIGATOR_215157] -home placement 
due to associated injuries [ McCall 2004] . After adjustment for many co nfounders, 
including the use of ant
idepressant or benzodiazepi[INVESTIGATOR_050], there is a 30–40% increased risk of 
subsequent falls with short sleep duration and poor sleep efficiency.  
 Treatments  1.1.3
The current standards  of care encompass  pharmacotherapy and non -pharmacological 
therapi[INVESTIGATOR_014] [ Schutte -Rodin 2008 ]. 
Non-pharmacologic al (psychological a nd behavioral)  standard -of-care therapi[INVESTIGATOR_42844] a variety of treatment methods such as  cognitive behavioral therapy 
(CBT), stimulus control, and relaxation training [ Schutte -Rodin 2008 ]. Sleep hygiene 
therapy is often added  to these treatment modalities.  However, this may not be the ideal 
course of treatment for all patients . Many patients  with insomnia are not interested in 
CBT, an d when they are, access to it may be limited by [CONTACT_42896][INVESTIGATOR_215158] [ Pi[INVESTIGATOR_42849] 2007, Schutte -Rodin 2008 ]. Pharmacologic al 
options may be warranted. 
Prescription of sleep medications (hypnotics) for the treatment of insomnia include 
benzodiazepi[INVESTIGATOR_1651], non -benzodiazepi[INVESTIGATOR_42845], melatonin 
agonists, the orexin receptor antagonist suvorexant, and low dose doxepin. 
Benzodiazepi[INVESTIGATOR_215159] a class of medications that bind to gamma -aminobutyric acid 
(GABA) type A receptor subtypes [ Lieberman 2007 ]. Drugs in this class , which include 
flurazepam, temazepam, trialozam, estazolam, and quazepam , were previously 
commonly prescribed for insomnia. While the efficacy of these medications has been 
well documented, their use fulness is limited by  [CONTACT_215209] 
(e.g., morning or next -day hangover), cognitive impairment (including anterograde 
amnesia), motor incoordination, and dependence [ Holbrook 2000, Buscemi 2007]. 
Benzodiazepi[INVESTIGATOR_215160] s
leep architecture: they prolong stage 2 sleep and may slightly 
reduce the relative amount of rapid eye movement (REM) sleep 
[Treat  Guidel Med  Lett 2009].  Their  use has been associat ed with tol erance development  
and rebound insomnia upon withdrawal of medication [ Kales 1978, Petursson 1981].   
Non-benzodiazepi[INVESTIGATOR_215161] a more targeted action on 
one or more GABA type A receptor su btypes. Zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_215162] -release 
(CR),  and zaleplon show affin ity for the alpha 1 receptor sub -type, while eszopi[INVESTIGATOR_215163] 2 and 3 receptor sub -types [ Nutt 2006] . All of these drugs 
reduce latency to sleep onse
t, but zolpi[INVESTIGATOR_215164] o nset (WASO), reflecting an improvement in sleep maintenance  
ACT -[ADDRESS_258670] 2016 , page 36/[ADDRESS_258671]  2016 -000827 -16 
Doc No D -16.394 
 
 
[Ambien® USPI , Lunesta® USPI ]. Although they have less impact on sleep arc hitecture, 
possibly by [CONTACT_215210]
r receptor selectivity, the drugs in this group have similar 
adverse effects as benzodiazepi[INVESTIGATOR_1651]. For example, 15% of subject s experienced 
anterograde amnesia after zolpi[INVESTIGATOR_215165], and in approximately 50% of those 
patients , it occurred within 30 minutes [ Praplan -Pahud 1990 ]. Zolpi[INVESTIGATOR_215166] [ Mets 2010]. This represents a safety concern for older 
people who use hypnotics [ Agostini 2004] ; about 1%
 of falls result in hip fractures that 
lead to restricted mobility for 60%, i
ncreased functional dependence for 25%, and death 
within 6 months for 25 % of the patients [ Avidan 2005 ]. In addition to these concerns, in 
2007 the US Food and Drug Administration (FDA) requested that all ma nufacturers of 
hypnotic drug products strengthen their product labeling to include stronger language related to potential risks. These risks include severe allergic reactions and complex sleep
-related behaviors  [FDA 2007] . 
Newer hypnotics that do not act at the GABA receptor  have been developed. The 
melatonin agonis
t ramelteon is approved for insomnia in the US and in Japan, but not in 
Europe. Ramelteon  reduces sleep latency and increases total sleep time (TST) but has no 
effect on WASO [ Kuriyama 2014] , making it an inappropriate treatment for subjects  with 
sleep maintenance problems [ Sim
pson 2008 ]. Ramelteon is devoid of next -day residual 
effects, withdrawal or rebound insomnia and does not appear to be associated with abuse liability.  
Low-dose doxepin (3 mg and 6 mg tablets) is indicated for insomnia characterized by 
[CONTACT_215211]. This drug appears to act through selective histamine
-1 receptor blockade [ Scharf 2008] .  
Suvorexant is an oral dual orexin receptor antagonist (DORA) that was approved by [CONTACT_1622] (2014 ) for the treatment of insomnia characterized by [CONTACT_215212] o nset 
and/or sleep maintenance . Suvorexant is contraindicated in patients with narcolepsy. 
Next
-day effects , including impaired driving performance, have been reported at 20 mg 
[Belsomra® USPI ]. Concerns related to driving safety led the FDA to approve suvorexant 
at a maximum dose of 20 mg per night [ Ve
rmeeren 2015 ], a lower dose than anticipated 
based on efficacy data with up to 40 mg. Next -day residual effects might be related to the 
long half -life (t ½ = 12 hours) of suvorexant [ Citrome 2014] . Rebound insomnia or 
withdrawal signs upon drug discontinuation w
ere not observed in clinical trials 
[Herring  2016].  
Generally, use of sleep medications among all subjects increases with age and is highest in the elderly [ Ohayon 2002, Ohayon 2010] . In Germa 
ny, 7.4% of women and 5% of 
men in the age group of 60–[ADDRESS_258672] 
once per week [ Schlack 2013] . In Italy, the prevalence of sleep medication use in the 
ACT -[ADDRESS_258673] 2016 , page 37/[ADDRESS_258674]  2016 -000827 -16 
Doc No D -16.394 
 
 
elderly is approximately twice higher than in [LOCATION_013] , and half of the subjects using 
sleep medications report daily use [ Ohayon 2002 ]. Benzodiazepi[INVESTIGATOR_215167] -quarters of all self -reported sleep medications in 
those countries [ Ohayon 2002, Ohayon 2010]. In the U S, the use of sleep medicat ions 
increases with age. U p to 7% in people aged 80 years and more report to use prescription 
sleep medications in the 30 days prior to a survey [Chong 2013] . 
Use of benzodiazepi[INVESTIGATOR_215168] a higher serum concentration of benzodiazepi[INVESTIGATOR_215169] [ McCall 2004 ]. Despi[INVESTIGATOR_215170], benzodiazepi[INVESTIGATOR_215171] (such as trazodone) are among the most popular classes of medications prescribed for elderly patients in the 
US. An analysis of inappropriate (risk >  benefit) psychotropic prescribing determined 
that antidepressant agents, anti
-anxiety drugs, and sedative -hypnotics were the drug 
classes most frequently prescribed to ambulatory elderly patients [ Mort  2000]  
 Unm et medical need  1.1.4
There are effective
 treatments for insomnia  in the elderly  [Schutte -Rodin 2008 ]. 
However, currently available treatments are limited to short -term use with the exception 
of eszopi[INVESTIGATOR_11123]  (in the US) , and caution and dose reduction are often advised in the 
elderly . Pharmacologic al treatments that address sleep onset problems alone do not 
provide relief to people with sleep maintenance difficulties, and treatments indicated for 
those with sleep maintenance problems may be associated with risks of cognitive 
impairment, postural instability, next -day residual sedation  and increased risk of falls  
[Neubauer 2014] . This represents an important unmet medical need. Moreover, the use of 
benzodiazepi[INVESTIGATOR_215172] [ McCall 2004 ] leading to hip and femur fractures, to increased 
disability and use of healthcare resources . There is also a need for a pharmacologic al 
treatment for insomnia disorder that address es the most prominent and pressing 
symptoms of insomnia without negatively impacting next -day functioning. ACT -541468 
is a DORA  that has been investigated so far  in nonclinical and early -phase clinical 
studies. Results of nonclinical and early -phase clinical studies  [Section 1.2.2 ] warrant the 
evaluation of ACT -[ADDRESS_258675] 2016 , page 38/[ADDRESS_258676]  2016 -000827 -16 
Doc No D -16.394 
 
 
1.2 Study treatment : ACT-541468 
 The orexin s ystem 1.2.1
The orexin system is involved in the regulation of sleep and arousal by [CONTACT_8360] (CNS) and is curre
ntly being targeted in the development of new 
therapi[INVESTIGATOR_215173].  
The neuropeptides orexin -A and orexin -B are synthesized in the lateral hypothalamic 
areas [de Lecea 1998 ] and activate the orexin -1 and orexin -2 receptors  [Kilduff 2000] . 
Nerve fibers from orexin neurons ma
ke projections to the basal forebrain, corticolimbic 
structures, and brainstem, particularly to those regions related to waking and regulation of sleep [ Hagan 1999, Sakurai  2007] . Infusing exogenous orexins into cerebral ventricles in 
rats leads to enhanced behavioral ac 
tivity, arousal, delayed onset of sleep, and 
maintenance of cortical activation  [Hagan 1999, Samson 2010 ]. Orexin -producing 
neurons are active during wakefulness and fall quiet during sleep [ Sakurai  2007 ]. 
Orexin -A levels in the cerebrospi[INVESTIGATOR_215174], being  highest during active wake periods [ Zeitzer 2003, 
Desarnaud  2004].  
Orexins may be implicated in the genesis of narcolepsy, due to findings of low cerebral spi[INVESTIGATOR_215175] [Mignot 2002 ] 
and near -complete atrophy of orexin neurons in post -mortem brains of patients with 
narcolepsy  [Thannickal 2000] , coupled with the observation of behavioral phenotypes 
consistent with narcolepsy in multip
le animal models of orexin  deficiency or dysfunction 
[Lin 1999] .  
One DORA, suvorexant, has shown efficacy in subjects with insomnia, and is approved 
notably in the US. For a descripti
on of the effects of suvorexant, refer to Section 1.1.3. 

ACT -[ADDRESS_258677] 2016 , page 39/[ADDRESS_258678] 2016 , page 40/[ADDRESS_258679] 2016 , page 41/[ADDRESS_258680] 2016 , page 42/[ADDRESS_258681] 2016 , page 43/[ADDRESS_258682] -541468 dose(s) that  
will show a favorable efficacy and safety profile and to assess the safety and tolerability 
of the compound in elderly subjects with insomnia disorder. 
The dose to be studie d in future clinical trials will be established based on the change in 
objectively assessed WASO and safety data, such as next -day residual effect from 
baseline versus placebo.  
 Rationale for study 1.3.[ADDRESS_258683] -541468 is a DORA. The orexin system is involved in the regulation of sleep and 
arousal . 
DORAs are efficacious in the treatment of insomnia disorder. Suvorexant, an oral DORA, demonstrated efficacy and was approved by [CONTACT_34033] 2014 for the treatment of 
insomnia characterized by [CONTACT_215213]/or sleep maintenance  in adults 
and elderly  [Citrome 2014]. Another DORA, almorexant, demonstrated objective and 
subjective improve 
ments in sleep maintenance and TST compared with placebo in two 
studies in subjects with primary insomnia.  
Elderly people exhibit a different sleep patter n than younger adults and the sensitivity of 
elderly and younger adults to the PD properties of a compound may differ. European guidelines therefore advise that the efficacy and the safe dose (range) of a drug must be defined in elderly, and they recommend a specific dose
-finding study in elderly subjects 
[EMA 2011 ]. This dose -finding study in the elderly will be performed in addition to a 
dose-finding study in adult subjects.  
The dose levels of 5, 10, 25, and [ADDRESS_258684] -541468 planned for this study were all 
investigated in Phase 1 studies , with clear sleep -promoting effects starting at 25 mg in  
healthy adult subjects. In healthy elderly subjects who received a single morning dose of 
15 mg, effects lasting >  [ADDRESS_258685] at 15 mg. No effects on the VAS Bond & Lader subjective alertness were obser ved at 5, [ADDRESS_258686] 2016 , page 44/[ADDRESS_258687] -541468 in insomnia disorder and 
identifying the compound’s efficacious and safe doses  in elderly with insomnia . 
1.[ADDRESS_258688] -541468 crosses the blood–brain barrier and decreases wakefulness in rats and dogs, 
is associated with a short sleep latency, and increases sleep efficacy following oral administration. In particular, it shows a shorter latency to non
-REM sleep and better sleep 
efficacy than suvorexant in rats and shorter duration of sleep in dogs. REM and 
non-REM sleep are prolonged proportionately in rats and dogs, thus decreasing 
wakefulness while preserving natural sleep architecture.  
This study will be the first study with the compound in elderly subjects with insomnia disorder. In humans, clear  and consistent  CNS
-depressant effects were observed at the 
morning dose of [ADDRESS_258689] 2016 , page 45/[ADDRESS_258690] -541468 metabolism is 
mainly dependent on CYP3A4; co -administration of ACT -[ADDRESS_258691] be avoided.  
Considering both the mode of action of DORA and common adverse reactions associated 
with the use of sleep medications, potential risks include: 
• Induction of next -day somnolence , which is associated with increased risk of 
impaired alertness and motor coordination.  
• Narcolepsy -like events . 
• Complex sleep -related behaviors, including night -time sleep driving and other 
complex behaviors while out of bed and not fully awake.  
• Suicidal thoughts and/or behavior.  
 Safety and risk- minimi zation measures taken in the present study  1.4.[ADDRESS_258692] the study centers .  
As required by [CONTACT_148188], the Columbia Suicide Severity Rating Scale 
(C-SSRS©) will be completed by [CONTACT_215214] ( PSG) nights at visit (V) [ADDRESS_258693] 2016 , page 46/[ADDRESS_258694] 2 hours after a meal.  
Elderly subjects enrolled in this study will receive the study treatment only at the sleep 
centers and will not be discharged from the sleep centers with the study treatment.  
Two c ommittees will be set up for the study:  
• An Independent Safety Board ( ISB) will review and adjudicate in a blinded manner 
all AE s of special in terest, i.e., narcolepsy -like events (e.g., excessive daytime 
sleepi[INVESTIGATOR_008], cataplexy), complex sleep behavior events and suicidal thoughts and/or behaviors. 
• An Independent Data Monitoring C ommittee (IDMC) will monitor safety and 
efficacy data in an unblinded manner and make appropriate recommendations to 
ensure safety of the subj ects. 
It is the investigator ’s responsibility to monitor the risk -benefit ratio of study treatment 
administration, as well as the degree of distress caused by [CONTACT_208207], and to discontinue study treatment or the study if, on balance, 
he/she believes that continuation would be detrimental to the subjects’ well
-being. 
In conclusion, based on available data on the study drug ACT -[ADDRESS_258695]  of this study in elderly  subjects with insomnia . The  short 
duration of the study ( five periods of  2 consecutive days’ exposure to study treatment  
separated by a wash -out of 5–12 days ), and the careful follow -up of subjects mandated by 
[CONTACT_215215]. 
[ADDRESS_258696] -541468 on 
latency to persistent sleep ( LPS)  on the first two days of each treatment period . 
2.[ADDRESS_258697] -541468 on other sleep parameters at each treatment period. 
Sleep parameters will include various objective and subjective measures 
[see Appendix 10] . 
ACT -[ADDRESS_258698] 2016 , page 47/[ADDRESS_258699] -541468 in elderly 
subjects with insomnia disorder. 
To explore the relationship between exposure (concentration of ACT -541468 
approximately 9 –[ADDRESS_258700] -dose at second morning of V3, V4, V5, V6, and V7) and 
safety.  
[ADDRESS_258701] approximately 50 subjects randomized, approximately 120 subjects will 
be screened  (estimated screen failure rate is up to  60%). Subjects will be  randomized 
1:1:1:1:1 to five different sequences of five  study treatments according to a Latin square 
design  [see Table 1]. The five  study treatments  are oral fixed doses of AC -541468 5 mg 
(D1), 10 mg ( D2), 25 mg ( D3) and 50 mg (D4), and placebo (P ).  
Table 1 Latin square design sequences  
 Periods  
1 2 3 4 5 
Sequence  1 Dose 4  Dose 2  Dose 3  Dose 1  Placebo  
2 Dose 2  Placebo  Dose 4  Dose 3  Dose 1  
3 Dose 3  Dose 1  Dose 2  Placebo  Dose 4  
4 Placebo  Dose 4  Dose 1  Dose 2  Dose 3  
5 Dose 1  Dose 3  Placebo  Dose 4  Dose 2  
 The study will be conducted in approximately 10 sites in two count
 ries (US and 
[LOCATION_013]) . 
Subjects who prematurely discontinue the study will not be replaced. Estimated dropout rate for th
e study is around 10%.  
No interim analysis is planned during the conduct of the study. Subjects who complete the study or
 prematurely discontinue the study w ill be treated with standard of care 
according to investigator’s opi[INVESTIGATOR_1649].  
ACT -[ADDRESS_258702] 2016 , page 48/[ADDRESS_258703]  2016 -000827 -16 
Doc No D -16.394 
 
 
 Study p hases  3.1.1
[IP_ADDRESS] Screening phase 
The screening phase  lasts a minimum of 14 days and a maximum of 28 days. It starts 
with the signature [CONTACT_42956] (ICF) and ends with subject 
randomization. It includes the screening period (from Day − 28 to Day − 7) and the run -in 
period (from Day − 14 to Day − 1). 
The screening period  starts with V1, which  occurs between Day − 28 and Day −[ADDRESS_258704] 7  consecutive days at 
home and until V2 .  
The run-in period  occurs between Day − 14 and Day −1 and starts with V2 . V2 consists 
of two  consecutive PSG nights on single -blind placebo treatment occurring between 
Day −14 and Day − 6. V2 is followed by 5 to 12 days at home with no treatment.  
[IP_ADDRESS] Double-blind treatment ph ase 
The double -blind t reatment phase  starts with the first  dose of study treatment in the first 
evening of the Randomization visit (V3) and ends in the second  morning of V 7. It 
consists of five  treatment  period s, each consisting of two  consecutive PSG nights on the 
assigned study treatment followed by a 5 - to 12 -day washout.  
The End of Treatment (EO T) is reached in the second morning  of V7, after the last 
dose of double -blind treatment and after all morning assessments  have been  performed.   
The safety Follow- up phase  starts after the EOT and lasts at least 30 days (i.e., until the 
second follow -up telephone call) . A first  telephone call is done 5 days (+ 7 days) after 
EOT to collect TE AEs from the last study treatment dose.  
The End of S tudy  (EOS) for a single subject i s defined as the date of the [ADDRESS_258705] to follow -up [see also Section  8.2], EOS is the date of last 
successful conta
ct for this subject. 
Unscheduled visits are allowed to take place anytime during the study, in which case 
study -related information will be collected.  
The visit schedule and protocol -mandated procedures will be performed according to the 
table of assessments [ Table 3]  and are described in S ection  7. 
The overa
ll study design is depi[INVESTIGATOR_123614] [ Figure 1].  
ACT -[ADDRESS_258706] 2016 , page 49/[ADDRESS_258707]  2016 -000827 -16 
Doc No D -16.394 
 
 
Figure 1 Study design  
 
V = visit; ▬ polysomnographic (PSG) nights ; D = dose; P = p lacebo . 
 
 Study duration 3.1.[ADDRESS_258708] of recruitment (i.e., ICF signe d) and ends with the last 
visit of the last subject.  
The double -blind treatment phase for each subject lasts [ADDRESS_258709], the study is completed with EOS (30 -day safety follow -up 
telephone call). The duration of participation in the study of a subject is expected to be 
approximately [ADDRESS_258710] 2016 , page 50/[ADDRESS_258711]  2016 -000827 -16 
Doc No D -16.394 
 
 
A crossover design was chosen due to the nature of the disease under investigation 
(i.e., chronic and stable), the short treatment duration (2 days for each dose), and the 
possibility to have a long wash -out period (5–12 days) compared to the t ½ (9.9 h) of 
ACT -541468 in elderly subjects . Furthermore, recruitment is anticipated to be 
challenging in the elderly population, and for this design , the  sample size required  in 
comparison with a parallel -group design is much smaller  [ICH 1998 ]. As a balanced 
complete block design, the five -sequence Latin  square crossover design minimizes the 
influence of confounding covariates because each patient serves as his or her own control 
(i.e., each subject will receive each of the four different doses of ACT -541468 and 
placebo). Any potential order (or learning) effect occurring over time will be averaged across all doses since each dose of ACT
-[ADDRESS_258712] -541468 was observed [ see Section [IP_ADDRESS] ], there is no need to expose subjects 
longer to reac
h study drug steady state. It is expected that the effect  on sleep parameters 
observed after  2 days ’ treatment  in elderly will evolve over time in a s imilar way  to what 
is seen in  adults treated over longer time [Herring  2016 ]. Effects  over longer time  in the 
elderly will therefore be extrapolated based on results of the dose -finding study in adults. 
3.3 Site staff and their roles : polysomnography technologists 
PSG re cordings must be performed by [CONTACT_215216] g 
techniques, described in the investigator site operations manual for the acquisition, processing, scoring, archiving, and transfer of digital PSG data (provided by [CONTACT_215217], 
NY). Technologists must be able to follow the procedures in this manual in order to 
produce technically acceptable tracings. Technologists are not required to be registered PSG technologists. 
Technologists must receive study -specific training prior to their  participation in the study. 
Adequate training for the PSG procedures will be conducted by [CONTACT_215218] ( CRO ; i.e., Clinilabs).  
Documentation of technologists ’ prior experience and training, and study -specific 
training, will be maintained at each clinical trials site.  
ACT -[ADDRESS_258713] 2016 , page 51/[ADDRESS_258714] , 
i.e., narcolepsy -like events (e.g., excessive daytime sleepi[INVESTIGATOR_008], cataplexy),  complex 
sleep -behavior events and suicidal thoughts and/or behaviors. The composition and 
operation of the ISB is described in the ISB charter.  
[ADDRESS_258715] population description  
This study will enroll elderly male and fema le subjects aged ≥  65 years with insomnia 
disorder. For more details on inclusion and exclusion criteria, please see S ection  4.3 and 
Section  4.4.  
Vulnerable subjects are non -eligible since the resea rch can be ca rried out in a 
non-vulnerable group of subjects and no particular benefit has been anticipated for 
vulnerable subjects that  would be different from  that in general population. 
Insufficient sleep quantity is operationalized in this study by a self -reported history of 
≥ 30 minutes to fall asleep and ≥  [ADDRESS_258716] 
≤ 6.[ADDRESS_258717] 7 consecutive days at home and until V2. They will also 
be validated by [CONTACT_215219]
-based criteria collected from 2  consecutive nights spent in 
a sleep laboratory during the run -in period. Poor s leep quality (SQ) is quantified  by [CONTACT_215220] S everity Index (ISI©) score ≥  15 at screening.  
4.2 Rationale for the selection of the study population . 
The study will recruit elderly subjects ( ≥ 65 years) . The selective inclusion of elderly 
subjects i s justified by  [CONTACT_215221]. A separate dose -finding study will be performed in 300 adult subjects.  
Gender has been described in the literature as one of the intrinsic factors influencing response to sleep medications , and the administration of the same dose of study drug 
might results in different drug exposure level in females and male subjects [ FDA 2013].  
Therefore, both m 
ale and female will be included in this study. 
ACT -[ADDRESS_258718] 2016 , page 52/[ADDRESS_258719] -541468 conducted in elderly subjects with 
insomnia disorders , concomitant treatments  for insomnia (pharmacological or not) or 
concomitant medications active in the CNS are not allowed in the study to avoid 
confounding effects on safety and efficacy of the study treatments. 
4.[ADDRESS_258720]  (V1 and V2 in brackets refer to the 
visits when the criteria must be assessed) : 
1. Signed informed consent prior to any study -mandated procedure (V1). 
2. Male or female aged ≥  65 years  (V1).  
3. Body mass index (BMI): 18.5 ≤  BMI (kg /m2) <  32.0 (V1). 
4. Insomnia disorder according to  DSM -5 criteria (V1).  
5. Self-reported history of all of the following on at least [ADDRESS_258721] 3 months prior to V1: 
5.1 ≥ 30 minutes  to fall asleep  
5.2 W ake time during sleep ≥ 30 minutes  
5.3 TS
T of ≤  6.5 h  
6. ISI© score ≥  15 (V1).  
7. Willing to comply with all aspects of the study protocol (V1 ). 
8. Ability to
 communicate well with the investigator, to understa nd the study 
requirements and judged by [CONTACT_215222], 
place, time and situation (V1).  
9. Meeting  the foll owing sleep parameters on at least 3 nights out of 7 consecutive 
nights on the  sleep diary completed at home between V1 and V2 (to be checked at 
V2):  
9.1 ≥ 30 minutes to fall asleep  
9.2 W ake time
 during sleep ≥ 30 minutes  
9.3 TS
T of ≤  6.5 hours  
10. Usu
al bedtime be tween 21:30 and 00:30 as reported on the sleep diary completed at 
home between V1  and V2 (to  be checked at V2) . 
11. Regular  time in b ed between 6 and 9 hours as reported on the sleep dia ry completed 
at home between V1 and V2 (to be checked at V2). 
12. Meeting  the fol low ing sleep parameters on the two PSG nights (V2):  
12.1 Mean LPS ≥ 20 minutes  ( with neither  of the two nights <  15 min utes), and 
12.2 Mean  WASO ≥  30 mi nutes  (with neither  of the two nights <  20 min utes), 
and 
12.[ADDRESS_258722] <  [ADDRESS_258723] 2016 , page 53/[ADDRESS_258724]  (V1 and V2 in brackets refer to the visits when 
the criteria must be assessed) : 
1. Any current sleep disorder (s) other tha n insomnia , or any lifetime history of related 
breathing disorder, periodic limb movement disorder, restless legs syndrome, 
circadian rhythm disorder, REM behavior disorder, or narcolepsy (V1). 
2. Self-reported usual daytime nappi[INVESTIGATOR_007] ≥  1 hour per day, and on ≥ 3 days per week 
(V1).  
3. Caffeine consumption ≥ 600 mg per day (V1) [ see Appendix 3] . 
4. Shift work within 2 weeks prior to the screening visit, or planned shift work during study (V1
).  
5. Travel ≥ three tim e zones within 1 week prior to the screening visit, or planned travel 
≥ three time zones during study (V1 ). 
6. Hematology  or bioche mistry test results deviating from the normal range to a 
clinically relevant extent as per judgment of the i nvestigator (V1 , V2)   
7. AST and/or ALT  > 2 × the U LN and/ or direct  bilirubin >  1.5 ×  ULN  (V1, V2) . 
8. Severe renal impairment: known or defined as estimated creatinine clearance < 30 mL/min, according to the 4
-variable Modification of D iet in R enal 
Disease formula (V1, V2) 
9. Unstable medical condition, significant medical dis order or acute illness within 
[ADDRESS_258725] ’s safety or interfere with the study assessments (V1).  
10. Systolic blood pressure (BP)  > 150 mmHg
  and diastolic BP  > 90 mmHg (V1 ,V2).  
11. Resting pulse rate <  50 or ≥  100 beats pe r minute ( V1, V2). 
12. Any of the following conditions related to corrected QT ( QTc) inte rvals (V1 ,V2):  
11.1 A prolonged QTc interval (QTc greater than 450 ms). In case of QTc greater than [ADDRESS_258726] is not eligible.  
11.2 A history of additional risk factors for torsade de pointes (e.g., heart failure, 
hypokalemia
, family history of long QT syndrome).  
13. Any of the following conditions related to suicidality:  
12.1 Any suicidal  ideation with intent with or without a plan at s creening , i.e., 
answering “ Yes” to questions 4 or 5 on the suicidal  ideation section of the 
screening / Baseline version of the C -SSRS© (V1, V2). 
12.2 Lifetime history of suicide attempt (V1).  
14. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as history of non
-compliance to medical 
ACT -[ADDRESS_258727] 2016 , page 54/[ADDRESS_258728] sleep, 
motor performance, or cognition, including Parkinson disease, predementia, 
dementia, other neurodegenerative disorders, and stroke (V1).  
15. Treatment with another investigational drug within 1 month prior to V1. 
16. Known hypersensi
tivity or contraindication to drugs of  the same class of the s tudy 
treatment or to any excipi[INVESTIGATOR_215176] (V1).  
17. Treatment  with prohibited CNS act ive drugs [ as defined in Appendix 4 ] for 
5 half -lives of the respective drug (but at least 2 weeks) prior to V1 and until 
24 hours after EOT , including over -the-counter (OTC) medication  and herbal 
medicines . 
18. CBT  within one month prior to V1.  
19. Treatment  with moderate to strong CYP3A4 inhibitors, CYP3A4 inducers , sensitive 
CYP3A4 substrates, P -glycoprotein 1 (P -gP) substrates, Breast Cancer Resistance 
Protein  (BCRP ) substrates, and CYP2B6 substrates  [as defined in Appendix 4 ] 
within [ADDRESS_258729] 3 consecutive 
days (V1).   
22. Positive  drug test (for benzodi azepi[INVESTIGATOR_1651], barbiturates, cannabinoids, opi[INVESTIGATOR_858], 
amphetamines, or cocaine) or presence of alcohol in exhaled breath as detected by a breathalyzer test ( V1,V2). 
23. Heavy tobacco use ( ≥ 10 cigarettes per
  day), and/ or inability to refrain from 
smoking for at least 14 hours during the night (V1).  
24. Apnea/hypopnea index (AHI) ≥  15/h on the first PS G screening night according to 
the American Academy of Sleep Medicine  (AASM ) criteria [ Meoli 2001, 
CMS  2008]  (V2).  
25. Apnea or hypopnea event (according to AASM criteria [ M eoli 2001, CMS  2008] ) 
associated with oxygen s
aturation by [CONTACT_406] (SpO 2) < 80% on the first PSG 
screening night (V2).  
26. Periodic limb movement with arousal index ( PLMAI) ≥  15/h on the first PSG  
screening night (V2).  
[ADDRESS_258730] 2016 , page 55/[ADDRESS_258731]  2016 -000827 -16 
Doc No D -16.394 
 
 
 Investigational t reatment and matching placebo: description and rationale 5.1.[ADDRESS_258732] -541468 doses will include: [ADDRESS_258733] -541468 -matching placebo is supplied by 
[CONTACT_215223], formulated with the inactive ingredients ( excipi[INVESTIGATOR_840] ) but 
without the active ingredient.  
 Study treatment administration  during the different study phases  5.1.[ADDRESS_258734] 2 hours after an evening meal (including 
V2). Each capsule will be swallowed whole. The date and time of treatment intake will 
be recorded by [CONTACT_215224] ( eCRF ). 
[IP_ADDRESS] Screening phase 
At V1, after signing the ICF and preferably prior to any study -mandated proced ures, the 
subject will be given the option to perform a swallow test with two placebo  capsules if 
he/she expresses any concern regarding her/his ability to swallow the study treatment. 
The test is to be done under the supervision of the site personnel and documented in the charts.  
At V2, in the evening of each of the two PSG nights, [ADDRESS_258735] -541468 -matching placebo will be taken  at the site . The capsules will be taken 
approximately 30 minutes before lights off (= habitual bedtime ±  5 minutes).  
[IP_ADDRESS] Double-blind t reatment phase 
During the double -blind treatment phase ( i.e., at V3, V4, V5, V6  and V7), ACT -541468 
and/or ACT -541468 -matching placebo will be taken  approximately 30 minutes before 
lights off  (= habitual bedtime ± 5 minutes) in the evening of each of the PSG nights , as 
shown in Table 2.  
ACT -[ADDRESS_258736] 2016 , page 56/[ADDRESS_258737]  2016 -000827 -16 
Doc No D -16.394 
 
 
Table 2 Number of capsules taken according to treatment dose 
 
Placebo (0)  5 10 25 
Placebo (0) [ADDRESS_258738] throughout the study.  
At V1 after the ICF has been fully signed, the investigator/delegate will contact [CONTACT_215225] (IRT) to get a subject number allocated to the 
subject.  
At V2 , subjects will receive single -blind placebo matching ACT -[ADDRESS_258739] meets all inclusion criteria and none of the 
exclusion criteria, the investigator/delegate contacts the IRT system  to randomize the 
subject. The IRT system  assigns a randomization number to the subject and assigns the 
treatment site kit number, which matches the treatment sequence assigned by [CONTACT_180490]. 
The randomization list is generated by [CONTACT_215226] O (ALMAC C linical 
Technologies – see contact [CONTACT_215227] 3 and in the IRT manual) and kept strictly 
confidentia
l. 
 Blinding  5.1.4
[IP_ADDRESS] Screening
 phase 
At V2, placebo matching ACT -[ADDRESS_258740] of the study will be unblinded to treatment. Treatment  
dose (mg) Dose strength  
(mg)  
ACT -[ADDRESS_258741] 2016 , page 57/[ADDRESS_258742]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS] Double-blind t reatment p hase 
From V [ADDRESS_258743] of the study. 
 Unblinding  5.1.5
[IP_ADDRESS] Unblin
ding for final analyses 
Full rand
omization information will be made available for data analysis only after 
database clo
sure in accordance with Actelion Quality System (QS) documents . 
[IP_ADDRESS] Unblinding for IDMC review 
An independent statistical a nalysis ce nter (ISAC), not otherwise involved in the design, 
conduct and analysis of the study, will have access to the randomization code in order to 
prepare unblinded reports for review by [CONTACT_31849] (for IDMC review meetings during the course of the trial). The randomization code will be made available to the ISAC in accordance with the sponsor’ s standard operating procedures ( SOPs ). 
[IP_ADDRESS] Unblinding for suspected unexpected serious adverse reaction  
If a sus
pected unexpected serious adverse reactio n (S[LOCATION_003]R ) occurs  for a subject 
participating in the study, Actelion Global Drug Safety will request the unblinding of the treatment assignment. The randomization code will not be communicated to the site staff or to the Actelion study team. Unblinded S[LOCATION_003]R  information will be provided to 
respective health authorities and institutional review boards ( IRBs ) / independent ethics 
committee ( IECs ) only. S[LOCATION_003]Rs will be reported to investigators in a blinded fashion. 
[IP_ADDRESS] Emergency procedure for unblinding  
The invest
igator, study staff and sponsor staff must remain blinded to the subject ’s study 
trea
tment assignment. The identity of the study treatment may be revealed only if the 
subject experiences a medical event, the management of which would require knowledge of the  blinded treatment assignment. In this case, the investigator can receive the 
unblinded randomization code for study treatment allocation through the IRT. In these situations, the decision to unblind resides solely with the investigator. Whenever it is 
possible, and if it does not interfere with (or does not delay) any decision in the best 
ACT -[ADDRESS_258744] 2016 , page 58/[ADDRESS_258745] be documented in the Investigator Site File 
(ISF) an
d eCRF.  
 Study treatment supply  5.1.6
Manufacture, labeling, packaging, and supply of study tr eatment will be  conducted 
according to Good Manufacturing Practice, Good Clinical Practice ( GCP ), and any local 
or national regulatory requirements. 
All study treatment supplies are to be used only in accordance with this protocol  and not 
for any
 other purpose. 
[IP_ADDRESS] Study treatment packaging and labeling 
Swallow test and  V2: 
Study treatment is supplied as a site kit and provided in childproof bottles containing 
36 capsules.  
V3 to V7: 
Study treatment is supplied as a site kit and provided in a wallet containing the 
[ADDRESS_258746] over the five  treatment  periods.  
Study treatment is labeled to comply with the applicable laws and regulations of the countries i n 
 which the study sites are located.  
[IP_ADDRESS] Study treatment distribution and storage 
Study tr
eatment supplies must be kept in an appropriate, secure area and stored according 
to the conditi
ons specified on the label. Temperature measurement devices for study 
treatment storage area are required.  
[IP_ADDRESS] Study treatment dispensing  
The study treatment will be kept at study site for administration by [CONTACT_215228]. The protocol -mandated study  
treatment dispen sing procedures must not be altered without prior written approval from 
Actelion. An accurate record of the date and amount of study treatment dispensed to each subject must be available for inspection at any time.  
ACT -[ADDRESS_258747] 2016 , page 59/[ADDRESS_258748]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS] Study treatment return and destruction  
The protocol -mandated study treatment return procedures may not be altered without 
prior written approval from Actelion. On an ongoing basis and/or on termination of the 
study, the Clinical Research Associate ( CRA ) will collect used and unused site kits , 
which will be sent to the warehouse, where Actelion staff or a deputy will check 
treatment reconciliation. In certain circumstances, used and unused study treatment containers may be destroyed at the site once study treatment accountability is finalized and has been checked by [CONTACT_215229]. 
 Study treatment accountability and compliance with study treatment  5.1.7
[IP_ADDRESS] Study treatment accountability  
The inventory of study treatment dispensed to the subject (i.e., study  treatment 
accountability) must be performed by [CONTACT_215230]. It is to be recorded by [CONTACT_215231], and checked by [CONTACT_215232]. The study
-treatment accountability log in the eCRF will include at least 
the following information for each study treatment unit  dispensed to the subject: 
At V2 (run -in): 
• Bottle number  
• Number of capsules dispensed 
Double -blind treatment phase  
• Dispensed site kit number 
• Date and Number of capsules administered . 
All study
 treatment supplies, including partially used or empty site kits  and bottles  must 
be retained at the site for review by [CONTACT_2689].  
[IP_ADDRESS] Study  treatm ent period s compliance 
Study treatment compliance is based on study treatment accountability. Study treatm ent 
compliance for each of the five  treatment periods will be calculated by [CONTACT_215233]. 
Compliance = [number of  capsules administered / total number of capsules that 
must have been taken during the period*] ×  100 
*The number of capsules for a treatment period equals 4. 
Complia nce during each  treatment period is expected to be 100%. Compliance values 
outside of this number will be considered as a protocol deviation, which will be reported 
in the eCRF by [CONTACT_2689]. The investigator must discuss the non -compliance with the 
ACT -[ADDRESS_258749] 2016 , page 60/[ADDRESS_258750] (e.g., tolerability
- or efficacy -related),  the investigator 
(e.g.,  due to pre -specified study treatment discontinuation criteria, an AE or lack of 
efficacy), or Actelion (e.g., study terminated) must be documented in the e CRF  and in the 
subject medical charts . 
A subject has the right to prematurely discontinue study treatment at any time , without 
any justification , by [CONTACT_215234] (i.e., premature withdrawal from the study  [see 
Section  8.2]) . Although a subject is not obliged to give his/her reason for prematurely 
withdrawin
g from the treatment or the study, it is recommended that the investigator 
makes a reasonable effort to ascertain the reason(s)  while full y respecting the subject ’s 
rights.  
The investigator must discontinue study treatment for a given subject if  he/she believ es 
that continued administration would be contrary to the best interests of the subject. 
A subject must be discontinued from the study in case of: 
• ALT ≥ 3 ×  the ULN a nd total Bilirubin > 2 ×  the ULN on the morning laboratory test 
following the second drug intake of each treatment period,  
or • ALT and / or AST > 5 ×  the ULN on the
  morning laboratory test following the 
second drug intake of each treatment period. 
A subject who prematurely discont inues study treatment is NOT  considered as withdrawn 
from the study and will be followed up until EOS  provided that the subject consent s to 
this limited participation in the study.  
Subjects who prematurely discontinue treatment during a treatment period at  the center 
will undergo the morning assessments after the last study drug intake. All  subject s who 
prematurely discontinue study treatment  will be asked to agree t o be called for the  safety 
ACT -[ADDRESS_258751] 2016 , page 61/[ADDRESS_258752]  2016 -000827 -16 
Doc No D -16.394 
 
 
follow -up (one telephone call  5 days [+ 7 days ] after the last intake of study treatment, 
and a second telephone call at least [ADDRESS_258753] intake of study treatment ).  
A subject who prematurely discontinues study treatment and withdraws consent to 
participate in any further study assessments is considered as withdrawn from the study. Subjects who die or are lost to follow
-up are also considered as withdrawn from the 
study. Withdrawal from the study and follow -up medical care of subjects withdrawn from 
the study is described in Sections 8.[ADDRESS_258754] dose of double -blind study treatment ( V7).  
 Reporting of previous/concomitant therapy in the e CRF  5.2.2
The use of  all study -concomitant therapy ( including tradit ional and alternative medicines  
e.g., plant -, animal -, or mineral -based medicines) will be recorded in the e CRF.  
Previous therapy must be recorded in the e CRF if discontinued less than 30 days prior to 
signi ng of the informed consent. 
The generic name, start/end dates of administration (as well as whether it was ongoing at 
start of tr
eatment and/or EOS), route, dose, and indication will be recorded in the e CRF.  
 Allowed concomitant therapy  5.2.[ADDRESS_258755] ’s well -being and not categorized as 
prohibited concomitant medications can be used in this study. However, initiation of new 
medications is to be discouraged and concomitant medications are preferably not to be 
changed during the course of the study. 
 Forbidden concomitant therapy  5.2.[ADDRESS_258756] 2016 , page 62/[ADDRESS_258757]  2016 -000827 -16 
Doc No D -16.394 
 
 
therapi[INVESTIGATOR_215177] (e.g. , cardiovascular disease, 
stroke).  
The following therapi[INVESTIGATOR_215155]: 
• Treatment with another investigational drug until the end of the safety follow -up 
phase.  
• Prohibited CNS -active medications, including OTC  medications and herbal 
medicines, until 24 hours after EOT [see Appendix 4 ]. 
• Treatment with moderate to strong CYP3A4 inhibitors , CYP3A4  inducers , sensitive 
CYP3A4 substrates  (i.e., have low bioavailability due to  a marked first -pass effect) , 
P-gP substrates, BCRP substrates and CYP2B6 substrates  until 24 hours after EOT 
[see Appendix 4] . 
• CBT and other psychological therapi[INVESTIGATOR_014], excluding common advice related to sleep 
hygiene , until 24 hours a
fter EOT . 
 Forbidden concomitant diet and activities  5.2.5
The following a
ctivities and diet are forbidden during the study: 
• Consumption of grapefruit and grapefruit juice until 24 hours after EOT. 
• Consumption of food wi
thin 2 hours prior to study treatment intake.  
• Caffeine cons
umption [more details in  Appendix 3]  
– > 600 mg/day 
– after 14:00 on the d
ays of PSG nights  
• Alcohol consumption [more details in  Appendix 2]:  
– > 2 drinks a day 
– with
in 24 hours prior to P
SG ni ght and during all PSG visits 
• Heavy tobacco use ( ≥ 10 cigaret tes per  day) and smoking during PSG assessment at  
night. At home, it is recommended not to smoke or to use other  tobacco products 
including oral snuff tobacco from 10 pm to 8 am .  
6 STUDY ENDPOINTS 
6.1 Efficacy endpoints 
 Primary efficacy endpoint  6.1.1The primary efficacy endpoint of this study is defined as the change of WASO (min) 
from Baseline
5 to Days 1 and 26 as determined by [CONTACT_63175] . 
                                                 
5 ‘Baseline’ is the mean of the two  PSG nights during run -in period (V2).  
6 ‘Days 1 and 2’  is the mean of the corresponding two  PSG treatment nights  for a given treatment period.  
ACT -[ADDRESS_258758] 2016 , page 63/[ADDRESS_258759]  2016 -000827 -16 
Doc No D -16.394 
 
 
WASO is the time (min utes) spent awake after onset of persistent sleep ( see definition of 
LPS in S ection  6.1.2)  until lights  on as determined b y PSG. WASO assessed by [CONTACT_215235] a 
sleep parameter evaluating sleep continuity. It is considered as an adequate endpoint for 
dose finding studies [ EMA 2011] .  
Total time in bed is fixed at  480 minutes  (8 hours) dur ing the PSG nights. The first 
screening PSG recording start s (lights off) within ± 30 minutes of usual bedtime 
(determined by [CONTACT_215236] V1 and V2); this time is then considered as the 
habitual bedtime and held constant ± 5 min throughout the study. PSG is recorded for 960 epochs of 30 seconds (8 hours) from lights off until lights on. PSG recording is centrally 
scored  by [CONTACT_215237] . 
 Secondary efficacy endpoint  6.1.2
The secondary e
fficacy endpoint of this study is  defined as the chan ge from Baseline5 to 
Days 1 and 26 in mean LPS.  
LPS is the time (min utes) from start of recording to the beginning of the first continuous 
20 epochs (i.e., 10 min utes) scored as non -wake, i.e., epochs scored  as either  sleep  
stage  1 (S 1), sleep  stage 2 (S2), sleep  stage  3 (slow -wave sleep [SWS])  or REM,  as 
determined  by [CONTACT_63175].  
 Other efficacy endpoints  6.1.3For each variable, multiple aspects will be considered in the analysis, in particular 
changes from bas
eline at different time p oints. Details are provided in Section 10.2.3:  
• Subjective WASO (sWASO), WASO overnight 
• Subjective LS
O (sLSO)  
• TS
T and subjective TST (sTST)  
• SQ 
• Sleep stage S
1, S2 , SWS and REM, 
•
 Shifts from S2, SWS or REM to S1 or wake 
• Wake time dur
ing sleep  
• Frequency of awakenings as measured by [CONTACT_215238] -reported  
• Sleep efficiency ( SE; defined as 100 ×  [TST / time in bed])  
• Next -day performance 
ACT -[ADDRESS_258760] 2016 , page 64/[ADDRESS_258761]  2016 -000827 -16 
Doc No D -16.394 
 
 
6.2 Safety endpoints  
• TEAEs7 up to 5 days after study treatment discontinuation  
• SAEs up to 30 days after study tre atmen t discontinuation 
• AEs leading to premature discontinuation of the double -blind study treatment 
• AEs of special in terest  starting or worsening after the first dose of the first treatment 
period until EOS (and after adjudication by [CONTACT_42892]): 
– Narcolepsy -like events (e.g., excessive daytime sleepi[INVESTIGATOR_008], cataplexy)  
– Complex sleep behavior events.  
– Suicidal thoughts and/or behaviors. 
• Change from Baseline (mean of the two PSG nights at V2, run -in period) to the 
Days  1 and 28 of each period  in vital signs ( systolic an d diastolic BP , pulse rate and 
body temperature) 
• Change from Baseline ( V1) to the second morning after the PSG nights at V7 in body 
weight  
• Treatment -emergent ECG abnormalities  from V3 until EOT  
• Change from B aseline (V2, second  morning) to the second morning after the PSG 
nights at V3, V4, V5, V6 and V7 in ECG parameters  
• Marked laboratory abnormalities on double -blind study treatment 
• Change from B aseline (V2, second  morning) to the second morning after the PSG 
nights at V3, V4, V5, V6 and V7 in labora tory variables  
• Change from B aseline ( mean of the two PSG nights  at V2, run -in period) to Days 1 
and 28 of each treatment period in: 
– Digit Symbol Substitution Test (DSST©) performed in the morning, 30 –60 
minutes after lights on  
– Sheehan  Disabil ity Scale (SDS©) performed in the morning, 30–60 minutes 
after lights on  
– Karolinska Sleepi[INVESTIGATOR_7110] ( KSS) perfor med in the morning, 30–60 minutes 
after lights on  
• Incidence of most severe suicidal ideation and suicidal behavior s according to  the 
C-SSRS© for each treatment period. 
                                                 
[ADDRESS_258762] 2016 , page 65/[ADDRESS_258763] -541468 (and possibly several of its metabolites) approximately  
9–[ADDRESS_258764] morning at these visits . 
7 VISIT SCHEDULE AND STUDY ASSESSMENTS 
7.1 Study visits  
The study visits are listed in  Table 3. For all double -blind treatment phase visits  (V3 to 
V7), the subjects must be seen between [ADDRESS_258765] be performed: one telephone call  5 days (+ 7 days) 
after the last intake of study treatment, and a second telephone call at least 30 days 
(+ 7 days) after the last intake of study treatment.  
 Screening/re- screening  7.1.[ADDRESS_258766] screening 
assessment is performed corresponds to the date of the s creening visit (V1).  
It is the responsibility of the investigator/delegate to obtain written informed consent 
from each subject participating in this study after adequate fa ce-to-face explanation of the 
objectives, methods and potential hazards of the study. The subjects who agree to participate in the study and the investigator/delegate must sign the ICF prior to any study
-related assessment or procedure.  
Subjects who are in the screening phase when the enrollment target has been met may 
still be randomized.  
It is permitted to re -screen subjects once, after discussion with Actelion.  All screening 
assessments must then be repeated at the time of re -screening (or as agreed with 
Actelion) . 
A swallow test will be proposed to subjects after signing the IC F and before starting any 
study -mandated procedures. The swallow test will be optional ; however, if a subject 
chooses to perform the swallow test but cannot swal low the study medication, he/she will 
be conside red a screen failure and will  be discontinued from the study. 
 Unscheduled visits  7.1.2
Unscheduled visits may be performed at any time during the study. Depending on the 
reason for t
he unscheduled visit (e.g., AE ), appropriate assessments will be performed 
based on the judgment of the investigator . Results of ECG, laboratory assessments and 
change in concomitant treatment will be recorded in the eCRF. After an unscheduled 
ACT -[ADDRESS_258767] 2016 , page 66/[ADDRESS_258768] continue according to the planned visit and 
assessment schedule [ Table 3] . 
 
ACT -[ADDRESS_258769] 2016 , page 69/[ADDRESS_258770]  2016 -000827 -16 
Doc No D -16.394 
 
 
 7.2 Study assessments 
The mandatory study assessments are listed in  Table 3.  
All study assessments are performed  by [CONTACT_215239] (medical, nursing, or 
specialist technical staff ) and are recorded in the e CRF, unless otherwise specified. Study 
assessments pe rformed during unscheduled  visits will also be recorded in the eCRF. The 
following order of assessments  is recommended:   
• In the evening before PSG night: 
– Physical examination (first evening)  
– Vital signs and body temperature (first evening)  
– Drug and alcohol test  
– Hematology and blood chemistry (first evening at V3, V4, V5, V6 and V7) 
– Evening questionnaire in sleep d iary, including VAS (second evening) 
– Recording of concomitant medications 
– AEs and SAEs  
– Study drug intake 30 minutes ( ± 5 minutes) before lights off 
• In the morning after PSG night, after completion of normal morning routine (e.g., 
using the bathroom, eating breakfast): 
– Physical examination (second morning at V7) 
– Vital signs and body temperature 
– DSST  
– SDS  
– KSS  
– C-SSRS 
– Morning questi
onnaire in sleep diary (including VAS)  
– Recording of concom itant medications  
– AEs and SAEs  
– Neurological examination*  
ACT -[ADDRESS_258771] 2016 , page 70/[ADDRESS_258772]  2016 -000827 -16 
Doc No D -16.394 
 
 
– Hematology and blood chemistry (second morning) 
– PK sampling * (second morning at V3, V4, V5, V6 and V7) 
– 12-lead ECG (
second morning)  
*The neurolog
ical examination must be performed approximately [ADDRESS_258773] PSG night, it is recommended to draw a PK 
sample  at this time . 
The foll owing assessments will be analyz ed by [CONTACT_42911]  (results will be 
transferred to  the Actelion database and to the investigators): 
• Lab parameters  
• ECG parameters  
• PSG recordings  
• Questionna
ires completed using a hand -held device (
listed below) 
If the pr
incipal in vestigator (PI) delegates any study procedure/assessment for a subject to 
an external facility, he/she must inform Actelion to whom these tasks are delegated. The 
set-up and oversig
ht will be agreed upon with Actelion. The supervision of any external 
facilities remains the responsibility of the PI . 
Calibrati
on certificates  / evidence o f equipment maintenance for the below -listed 
equipme
nt used to perform study assessments must be available prior to the screening of 
the first subject. Calibration certificates of other equipment must be available as per local requirements.  
• Temperatu
re measurement devices for study treatment storage area  
• PSG device  
 
Use of hand -held device 
Patients will be required to complete the following questionnaires on a hand -held device:  
ISI, SDS, KSS, C -SSRS, sleep diary  and VAS .  
Sites  will be
 properly trained on the accurate use of the hand -held devic e by [CONTACT_215240]. Data collected from the  hand
-held devic
e will be electronically 
transferred to Actelion  by [CONTACT_2024].  
For further d
etails refer to the hand -held device m
anual.  
ACT -[ADDRESS_258774] 2016 , page 71/[ADDRESS_258775]  2016 -000827 -16 
Doc No D -16.394 
 
 
 Demographics 7.2.1
Demographic data to be coll ected in the e CRF for all subjects include: a ge, sex, race and 
ethnicity. Relevant medical history  / current medical conditions (e.g., chronic and 
ongoing acute conditions, serious past conditions) present before signing informed 
consent will be recorded on the medical history page in the e CRF . Where possible, 
diagnoses and not symptoms will be recorded.  
 Insomnia severity index 7.2.2
The ISI assesses the severity of a subject ’s insomnia b y scoring the severity of 
sleep -onset and sleep
 maintenance difficulties and any insomnia -related interfe
rence with 
daytime functioning [ see Appendix 6 ]. The assessm
ent is on a 5 -point scale (0 –4
), where 
the composite score is obtained by [CONTACT_215241] ’s perception of his or her insomnia. A score of 15–21 indicates a moderate level 
of insomnia and a score of 22–28 indicates severe insomnia. An ISI total score 
< [ADDRESS_258776] ’s subjective -rated insomnia s
ymptoms, daytime 
impairment, and quality of life have improved to the minimal -to-none range [ Morin 1993, 
Scharf
 2007 ]. The ISI© will be completed by [CONTACT_42918] -held device.  
Actelion has been
 granted license agreement for the use of ISI. 
 Efficacy assessments  7.2.3
[IP_ADDRESS] Polysomnography 
PSG data will be used to assess objective sleep parameters (WASO and LPS) as well as 
data on sleep architecture (sleep stages). The PSG  data are evaluated and scored centrally 
by [CONTACT_215242]  (expert from  CRO Clinilabs, NY , not otherwise involved in the 
study ). The technical requirements for montage and recording of the PSG are outlined in 
the PSG manual. The quality of PSG recordings is monitored and quality controlled on an 
ongoing basis.  
All PSG recordings are supervised by [CONTACT_215243]. The site and scorers that 
participate in this study must be certified by [CONTACT_2024].  
The first screening  PSG recording  starts  (lights  off) within  ± 30 minutes of usual 
bedtime (determined by [CONTACT_215244] V1 and V2); this time  is then considered 
as the habitual bedtime and held  constan t (± 5 minutes)  throughout the study. Study 
medication  is admin istered  30 minutes (± 5 min utes) before the recording starts. The 
PSG recording is stopped after [ADDRESS_258777] PSG screening night (at V2) also includes AHI, PLMAI, and SpO
2. 
ACT -[ADDRESS_258778] 2016 , page 72/[ADDRESS_258779] be conducted in a sleep laboratory environment 
that meets the guidelines for sleep disorder centers [ aasmnet.org ]. 
During the PS
G recording,  the subject is requested to stay in bed and remain  connected  
to the recording  equipment. However , if the subject  needs  to go to the bathroom, he or 
she may do so and will be disconnected  for this short time from the recording device.  
Alternatively , urine flasks or bedpans may be provided. The subj ect must be re -connected 
as quic
kly as possible. The  time during which  the subject  is disconnected  will be 
scored  as time awake.  The subject  is not permitted  to perform any activit y (such  as 
reading,  listenin g to radio, etc.)  and is recommended not to have access to any watch or 
mobile phone device . The lights remai n switched  off unti l the [ADDRESS_258780] is then allowed to go to the bathroom and to get dressed. Within 
30–[ADDRESS_258781] the study centers.  
The centers  are requ
ired to transfer PSG data to the CRO responsible for central  scoring, 
after each secon d PSG night. Durin g the run-in period, PSG data 
obviously not fitting  
eligibil ity criteria  according to site scoring  (more than 10% deviation from protocol 
range)  are not required  to be sent  for central  scoring. If anything  prevents an y PSG night 
being scored, the  center  must  contact [CONTACT_215245]. The CRO will score 
the PSG data immediatel y upon receipt  and the center  will receive  the complete 
eligibility ass essment  (mean WASO,  mean LPS,  mean TST,  AHI, PLMAI, and the 
presence of any apnea/hypopnea event associated with Sp O2 < 80%) within 3 business  
days following the file’s receipt by [CONTACT_2024] . Based  on this information, the  investigator  
assesses the subject ’s potential eligibility.  
After the last PSG night at Visit [ADDRESS_258782]  (V2, V3, 
V4, V5, V 6 and V7) are sent by [CONTACT_215246]. The following sleep variables will 
be assessed by [CONTACT_63175]: WASO, LPS, TST, sleep stages S1 (called N1 in the scoring procedures of the Clinilabs manual) , S2 (N2), SWS (N3) and REM (R), wake time during 
sleep (W). The definitions of the sleep variables are given in the scoring procedures of the Clinilabs m anual.  
Incidental findings identified by [CONTACT_215247] . If the 
incidental findings are considered clinically relevant by [CONTACT_978] , they will be reported in 
the medical his tory or as an AE, as applicable.  
ACT -[ADDRESS_258783] 2016 , page 73/[ADDRESS_258784]  2016 -000827 -16 
Doc No D -16.394 
 
 
For more detailed information, refer to the ‘I nvestigator site operations manual for the 
acquisition, processing, scoring, archiving, and transfer of digital PSG  data (provided by 
[CONTACT_215217], NY) ’. 
[IP_ADDRESS] Sleep diary 
The sleep d iary is provi
ded to the subject at  V1 as an electronic hand -held device, 
prog
ramme d in the subject ’s language , and must be completed at home every day for at 
least [ADDRESS_258785] will complete the sleep diary evening questionnaire and VAS.  
[IP_ADDRESS].[ADDRESS_258786] information on self -reported sleep ch
aracteristics (sl eep induction 
and maintenance) and  bedtime and timing of study treatment intake.  
For further d
etails, see Appendix 9.  
[IP_ADDRESS].[ADDRESS_258787] information  on quality of sleep, depth of sleep,  mornin g sleepi[INVESTIGATOR_008],  
daytime alertness, and daytime ability to function, by [CONTACT_215248] a mark on  a VAS . 
Self-reported qualit
y of sleep, depth of sleep and morning sleepi[INVESTIGATOR_215178]. Self-reported da
ytime alertness and daytime ability to fun ction are assessed in 
the evening.  
For further d
etails, see Appendix 9.  
 Safety assessments  7.2.4
The definitions, r
eporting and follow -up of AEs and SAE
s are described in Section  9. 
[IP_ADDRESS] Weight and h e
ight 
Height will be measured at V1  only and recorded in the eCRF. 
Body weight wi
ll be measured at V1 and in the second morning of  V7 (recommended 
within [ADDRESS_258788] dose  of double -blind study drug i
ntake)  and recorded in the 
eCRF. BMI will be calculated according to the BMI formula (weight in kg/m2) and 
displayed automatically upon entry of weight and height in the eCRF.  
ACT -[ADDRESS_258789] 2016 , page 74/[ADDRESS_258790]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS] Vital signs  
Systolic and
 diastolic BP, pulse rate and body t emperature will be measured 
non-invasively
 at each study visit (i.e. , V1 as well as first evening and each morning at 
V2, V3, V4, V5, V6 and V7) . Vital signs will be measured with the subject either in a 
supi[INVESTIGATOR_51115]. It is recommen ded to allow the  subject to rest for at least 
5 minutes  and to use the same position (supi[INVESTIGATOR_103169]) throughout the trial for an 
individual subject. The right or left arm may be used, but it is recommended to use the 
same arm throughout the trial.  
Vital sign meas
urement and conditions will be collected in the eCRF.  
[IP_ADDRESS] Physical examination  
Physical
 examination is to be performed at V1 and on the second morning of V7  
(recommended within [ADDRESS_258791] dose of double -blind study dru
g intake)  as well 
as on the first evening at V2, V3, V4, V5, V6 and V7. It includes the examination of  the 
following body systems: 
• Head, ear, nos
e and throat 
• Eyes  
• Neck  
• Cardiovascular system  
• Respi[INVESTIGATOR_2133]  
• Abdomen 
• Skin 
• Extremities  
• Neurological system  
• Musculoskel etal system  
Other exams will be performed if indicated, based on medical history and/or symptoms. 
Information for all physical examinations must be included in the source documentation 
at the study site.  The observations must be recorded according to body system . In the 
event of an abnormality, the related signs (e.g., systolic murmur)  and not the diagnosis 
(e.g., mitral valve insufficiency)  must be recorded in the eCRF . Clinically relevant 
findings (other than those related to insomnia disorder), including smoking habits that are 
present prior to signing of informed consent, must be recorded on the Medical History eCRF form. Physical examination findings made after signing of informed consent  that 
meet the definition of an AE [Section  9.1.1]  must be recorded on the AE form of the 
eCRF.  
ACT -[ADDRESS_258792] 2016 , page 75/[ADDRESS_258793]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS] Digit Symbol Substitution Test 
The DSST is to be performed each morning after a PSG night  at V2, V3, V4, V5, V6 
and V7. The DSST is a measur e of attention,  perceptual  speed,  motor speed,  visual 
scannin g and memory. 
On a sheet  of paper , the subject  is given 120 seconds to complete as many 
substitutions as possible, entering  a symbol in numbered boxes  according  to a key 
shown on the top of the sheet (9  symbols).  
The centers  are provided with eight  different test versions that use the same symbols in a 
different sequence.  At each administration,  a different test  version is assigned  amon g the 
eight  versions, in order to minimize the impact of symbol/coding learning from one test 
to the subsequent one. 
The number of correct  substitutions is recorded  as the total DSST score.  
Actelion has been granted a license agreement for the use of the DSST. For further 
details,  see Appendix 5  
[IP_ADDRESS] Sheehan Disability Scale 
The SDS is to be performed each morning after a PSG night  at V2, V3, V4, V5, V6 and 
V7. The SDS consists of three  questions on impairment of work, social life, and family 
life/home responsibilities [ Appendix 7, Sheehan 1996 ]. The SDS is a self -administered 
questionnaire on the ha
nd-held device. Actelio
n has been granted the license agreement 
for the use SDS. 
[IP_ADDRESS] Karolinska Sleepi
[INVESTIGATOR_215179] a PSG night  at V2, V3, V4, V5, V6 and 
V7. The KSS will be used to assess next -day alertness  [see Appendix 8 ]. The s ubject will 
be aske
d to mark his/her sleepi[INVESTIGATOR_97412] a 9 -point scale. The sc
ale has a range from 1 being 
‘very alert ’ to 9 being ‘ very sleepy, great effort to keep awake, fighting sleep ’. The KSS 
is a self -administered ques
tionnaire on the hand -held device.  
[IP_ADDRESS] Columbia Suicide Severity Rating Scale 
The C -SSRS is to be performed at V1 and on each morning after a PSG night  at V2, V3, 
V4, V5, V6 and V7. The C -SSRS is an instrument that reports the severity of both 
suicidal ideation and behavior [ Posner 2007 ]. Suicidal ideatio
n is classified on a 5 -item 
scale:  
1. wish to be dead 
2. nonspe
cific active suicidal thoughts 
ACT -[ADDRESS_258794] 2016 , page 76/[ADDRESS_258795]  2016 -000827 -16 
Doc No D -16.394 
 
 
3. active suicidal ideation with any methods (not plan) without intent to act 
4. active suicidal ideation with some intent to act, without specific plan  
5. active suicidal ideation with specific plan and intent 
The C -SSRS also captures information about the intensity of ideation, specifically the 
frequency, duration, controllability, deterrents, and reasons for the most severe types of 
ideation. In addition, the C -SSRS captures information using yes/no question and 
answers on suicidal behavior, specifically actual, interrupted, and aborted attempts; 
preparatory acts  or behavior; and if suicidal behavior was present during the assessment 
period. More than one classification can be selected provided they represent separate epi[INVESTIGATOR_1841]. For actual attempts only, the actual or potential lethality is classified for the 
initial, most lethal, and most recent attempts. The C
-SSRS will be completed at all study 
visits. At V 1 (screening) the C -SSRS will be completed for the subject lifetime history 
of suicidal ideation and behavior. At all other visits, the C -SSRS will be completed for 
ideation and behavior since the previous visit.  
At each visit
, the investigator will review the responses provided by [CONTACT_215249]. The scale will be self -administere
d using the hand -held device  in the
 
presence of an adequately trained staff member .  
Actelion has b
een granted the license agreement for the use of the electronic C -SSRS.  
[IP_ADDRESS] Neurological
 examinations 
In the morning following each PSG night (V2, V3, V4, V5, V6 and V7) , a set of 
examinations must be performed approximately 1 hour after lights on  [see S ection 7.2]. 
The neurologi
cal examinations will be done by [CONTACT_093], a delegated physician, a 
specialist nurse or a nurse practitioner, trained according to local requirements and local 
clinical practice. The following examinations will be perf ormed to detect a possible 
next-day residual
 effect :  
• Gait 
• Tandem w
alking  
• Romberg t est. 
The set of examinations will be repeated approximately every [ADDRESS_258796] the center [ see Section 7.2]. The time when it is considered safe 
for the subject to leave the center  will be recorded in the eCRF. 
[IP_ADDRESS] ECG assessment  
A standard [ADDRESS_258797] 2016 , page 77/[ADDRESS_258798]  in the supi[INVESTIGATOR_19636] a 
5-minute  period. Dat
a records will be sent to the evaluation center for central reading.  
Details wi
ll be provided in the 12 -lead ECG labor
atory manual.  
The following par
ameters will be evaluated:  PQ or PR (ms), QRS  (ms), QT (ms), heart  
rate [HR] (bpm), and rhythm. QT C (ms) will be calculated according to  
• Bazett ’s formula: QT C = QT / (RR)1/2 
and 
• Fridericia’ s formula: QT C = QT / (RR)1/3, where RR = 60 / HR 
If the central review of the ECG detects a prolonged QTc interval greater than [ADDRESS_258799] at screening (V1 , V2), ECG must be repeated (at least [ADDRESS_258800] 
ECG on the same day). If the central review confirms that the repeated ECG shows a 
QTc interval greater than [ADDRESS_258801] be recorded in the eCRF.  
ECG data collected by [CONTACT_215250] b e electronically transferred to  Actelion.  
 Laboratory assessments 7.2.5
[IP_ADDRESS] Type of laboratory 
A central labor
atory (see central laboratory manual for contact [CONTACT_8972]) will be used for all 
protocol -mandated labor
atory tests, including re -tests due to la
boratory abnormalities and 
laboratory tests performed at unscheduled visits.  
Except ional circu
mstances that  will require recording of local laboratory results of the 
parameters described in S ection [IP_ADDRESS] (with corresponding normal ranges), include 
hospi[INVESTIGATOR_42860] a medical emergency, and missing central laboratory 
results from a scheduled or unscheduled visit.  
If one centra
l laboratory sample is lost or cannot be analyzed for whatever reason, the 
investigato r will collect an additional sample as soon as possible for repeat analysis, 
unless a local laboratory sample was collected within the same time -window and these
 
test results are available.  
Central labor
atory reports will be sent to the investigator. In ca se of specific (pre -defined) 
labo
ratory abnormalities, the central laboratory will alert Actelion and the concerned site. 
Alert flags that will trigger such notifications are displayed in  Appendix 1.  
Al
l laboratory reports must be reviewed, signed and dated by [CONTACT_42920] [ADDRESS_258802] 2016 , page 78/[ADDRESS_258803]  2016 -000827 -16 
Doc No D -16.394 
 
 
investigator/delegate  must indicate on the laboratory report whether abnormal values are 
considered clinically relevant or not. Clinically relevant laboratory findings that are 
known at the time of signature [CONTACT_215272] t he eCRF. Any clinically relevant laboratory abnormalities detected after 
signature [CONTACT_215273] [see Section 9] and must be followed until the value returns to within the normal range or is 
stable, or until the change is no longer clinically relevant.  
Details about the collection, sampling, storage, shipment procedures, and reporting of 
results and abnormal findings can be found in the laboratory manual. 
[IP_ADDRESS] Laboratory tests 
Hematology  
• Hemoglobin (g/L) 
• Hematocrit  (L/L)  
• Erythrocytes (109/L) 
• Reticulocyte s (%) 
• Leukocytes with differential counts (109/L) 
• Platelet s (109/L) 
• Prothrombin time and international normalized ratio  
Clinical chemistry  
• ALT (U/L)  
• AST (U/L)  
• Alkaline phosphatase (U/L) 
• Creatine kinase (mcg/L)  
• Total and direct bilirubin (μmol/L)  
• Gamma -glutamyl t
ransferase (U/L)  
• Creatinine
 (μmol/L)  
• Blood urea nitrogen (mmol/L)  
• Uric acid (μmol/L)  
• Glucose ( mmol/L)  
• Cholesterol, triglycerides (mmol/L)  
• Sodium, potassium, chloride, calcium (mmol/L) 
• Albumin (g/L) 
• Thyroid hor
mones (triiodothyronine, thyroxine), and thyroid -stimulating hor
mone  
ACT -[ADDRESS_258804] 2016 , page 79/[ADDRESS_258805]  2016 -000827 -16 
Doc No D -16.394 
 
 
Other tests  
The urine drug screening kits (testing for presence of benzodiazepi[INVESTIGATOR_1651], barbiturates, 
cannabinoids, opi[INVESTIGATOR_858], amphetamines, or cocaine) and the breathalyzer for alcohol 
detection in the exhaled breath will be provided by [CONTACT_6626].  
Study drug is administered as described in S ection 5 only if the results of these other tests 
are negative.  
 Pharmacokinetic assessments  7.2.6
PK samples w
ill be collected in the morning after the secon d PSG night after lights on, 
approximately 9 –[ADDRESS_258806]-STUDY TREATMENT / 
MEDICAL CARE 
8.[ADDRESS_258807] completed the study as per protocol. 
8.2 Premature withdrawal from study 
Subjects may voluntarily withdraw from the study without justification for any reason at 
any time. Subjects are considered withdrawn if they state an intention to withdraw further 
participation in all components of the study (i.e., withdrawal of consent), die, or are lost to follow
-up. If a subjec
t withdraws consent, no further data will be coll ected in the e CRF 
from the date of withdrawal onward. The investigator may withdraw a subject from the study (without regard to the subject ’s consent) if he/she believes that continued 
participation in the study would be contrary to the best interests of t he subject. 
Withdrawal from the study may also result from a decision by [CONTACT_180505], including premature termination or suspension of the study. 
Subjects ar
e considered as lost to follow -up if all rea
sonable attempts by [CONTACT_215251]. The site must take preventive measures to 
avoid a subject being lost to follow -up (e.g., docu
ment different ways of contact [CONTACT_42923], home address, email address, person to be contact[CONTACT_215252] -[ADDRESS_258808] 2016 , page 80/[ADDRESS_258809]  2016 -000827 -16 
Doc No D -16.394 
 
 
cannot be reached). If the subject cannot be reached, the site must make a reasonable 
effort to contact [CONTACT_423], document all attempts, and enter the loss of follow -up 
information i
nto the e CRF. The following methods must be used: a t least three telephon e 
calls must be placed to the last available telephone number and one registered letter must be sent by [CONTACT_215253]. Additional methods may be acceptable if they are compliant with local rules/regulations (e.g., a visit by [CONTACT_215254] ’s 
home), respecting the subject ’s right to privacy. If the subject is still unreachable after all 
contact [CONTACT_42927], he/she will be considered to be lost to follow
-up. 
If premature w
ithdrawal occurs for any reason, the reas on (if known) for premature 
withdrawal from the study, along with who made the decision (subject, investigator, or Actelion staff ) must be recorded in the eCRF, if known. 
If for whate
ver reason (except death or loss -to-follow -up) a subject is
 withdrawn from the 
study, the investigator must make efforts to schedule a last appointment  / telephone call 
to assess the safety and well -being of the subj
ect, and discuss follow -up medical care.
 
Data obtained during this last appointment  / telephone call will be reco rded in the 
subjects ’ medical records but it will not be collected in the e CRF. The investigator must 
provide follow -up medical care f
or all subjects who are prematurely withdrawn from the 
study, or must refer them for appropriate ongoing care, as described in Section 8.4. 
8.3 Premature termination or suspension of the study  
Actelion reserves the right to terminate the study at any time globally or locally. Investigators can terminate the participation of their site in the study at any time.  
If a study is prematurely suspended or terminated, Actelion will promptly inform the investigators, the IECs/IRBs, and health au thorities, as appropriate, and provide the 
reasons for the suspension or termination. 
If the study i
s suspended or prematurely terminated for any reason, the investigator  – in 
agreement with Actelion – must promptly inform all enrolled subjects and ensure their 
appropriate treatment and follow -up, as described i
n Section 8.4. Actelion may
 inform 
the investigator of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subjects’ interests.  
In addition, if the investigator suspends or terminates the participation of his/her site to the study without prior agreement from Actelion, the investigator must promptly inform 
Actelion staff and the IEC/IRB, and provide both with a detailed written explanation of 
the termination or suspension. 
If the IEC/IRB suspends or terminates its approval  / favorable opi[INVESTIGATOR_1101] a study, the 
investigator must promptly notify Actelion staff  and provide a detailed written 
explanation of the termination or suspension. 
ACT -[ADDRESS_258810] 2016 , page 81/[ADDRESS_258811]  2016 -000827 -16 
Doc No D -16.394 
 
 
8.4 Medical care of subjects after study completion / withdrawal from study 
After the subject ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to subjects what treatment(s) / medical care 
is necessary and available according to local regulations. 
[ADDRESS_258812] during the course of the study, whether or not considered by [CONTACT_86190].  
A TEAE is any AE temporally associated with the use of study treatment (from Day [ADDRESS_258813]  study drug intake in each treatment period and until 5 days after 
study treatment discontinuation) whether or not considered by [CONTACT_86190].  
AEs include: 
• Exacerbati
on of a pre -existing
 disease.  
• Increase i
n frequency or intensity of a pre -existing
 epi[INVESTIGATOR_42861]. 
• Diseas
e or medical condition detected or diagnosed during the course of the study 
even though it may have been present prior to the start of the study. 
• Continuous persistent di sease or symptoms present at study start that worsen 
following the signing of informed consent. 
• Abnormal assessments, e.g., change on physical examination, ECG findings, if they 
represent a clinically significant finding that was not present at study start or 
worsened during the course of the study. 
• Laboratory test abnormalities if they represent a clinically significant finding, 
symptomatic or not, which was not present at study start or worsened during the 
course of the study or led to dose reduction, interruption or permanent discontinuation of study treatment.  
Overdose, misuse, abuse of the study treatment and study treatment errors will be reported as an AE.  
 Intensity of adverse events  9.1.2
The intens
ity of clinical AEs is graded on a three -point scal
e – mild, moderate, severe – 
and is reported on a specific AE form of the eCRF.  
ACT -[ADDRESS_258814] 2016 , page 82/[ADDRESS_258815] be reported adding a new log line on the AE form. The onset date reported on the new log line corresponds to the date of worsening in intensity.  
The three categories of intensity are defined as follows:  
 Mild  
The event may be noticeable to the subject. It does not usually influence daily activities, and normally does not require intervention. 
 Modera te 
The event may make the subject uncomfortable. Performance of daily activities may be influenced, and intervention may be needed. 
 Severe  
The event may cause noticeable discomfort, and usually interferes with daily activities. 
The subject may not be able to continue in the study, and treatment or intervention is 
usually needed. 
A mild, moderate, or severe AE may or may not be serious [see Section 9.2 ]. These term
s 
are used to describe the intensity of a specific event. Medical judgment must be used on a 
case-by-case basis.  
Seriousness
, rather than intensity assessment, determines the regulatory reporting 
obligations. 
 Relationship to study treatment  9.1.[ADDRESS_258816] 2016 , page 83/[ADDRESS_258817] ’s EOS telephone call will not be 
collected by [CONTACT_180494].  
9.[ADDRESS_258818] one of the 
following criteria:  
• Fatal.  
• Life-threatenin
g: Refers to an event in which the subject was at risk of death at the 
time of the event. It does not refer to an event that hypothetically might have caused death had it been more severe.  
• Requiring
 in-patient hos
pi[INVESTIGATOR_869]. 
• Resulting
 in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medicall
y significant: Refers to important medical events that may not immediately 
result in death, be life -threateni
ng, or require hospi[INVESTIGATOR_42862], based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes lis ted in the definitions above. 
The followi
ng reasons for hospi[INVESTIGATOR_42863]: 
1. Hospi[INVESTIGATOR_180458], or social and/or convenience reasons.  
2. Hospi[INVESTIGATOR_215180] -planned (i.
e., planned prior to signing informe d consent) 
surgery or standard monitoring of a pre -existing dis
ease or medical condition that 
did not worsen, e.g., hospi[INVESTIGATOR_42865] a subject with stable angina pectoris.  
However, com
plications that occur during hospi[INVESTIGATOR_42866] (e.g., if a 
complication prolongs hospi[INVESTIGATOR_059]). 
 Reporting of serious adverse events  9.2.[ADDRESS_258819] 2016 , page 84/[ADDRESS_258820] a 
reasonable possibility of a causal relations hip to either the study design or to 
protocol -mandated pro
cedures (e.g., discontinuation of a subject ’s previous treatment 
during a washout period, leading to exacerbation of underlying disease).  
 Follow- up o
f serious adverse events  9.2.[ADDRESS_258821] ’s EOS tele phone call must be reported to 
Actelion Global Drug Safety, but it is not recorded in the e CRF.  
 After the [ADDRESS_258822]
 be reported to Actelion 
Global Drug Safety  within 24  hours of the investigator ’s knowledge of the event, only if 
considered by [CONTACT_42930].  
 Reporting
 procedures  9.2.[ADDRESS_258823] be reported by [CONTACT_215255] 24 hours of the investigator’ s first kn owledge of the event. 
All SAEs must be recorded on an SAE form, irrespective of the study treatment received 
by [CONTACT_423], and whether or not this event is considered by [CONTACT_41708].  
The SAE forms must be sent to the Actelion Global Drug Safety department (contact 
[CONTACT_180514]). The investigator must c omplete the SAE form in 
English  and must assess the event ’s causal relationship to the study treatment.  
Any relevant information from source documents regarding the SAE, e.g., hospi[INVESTIGATOR_215181], etc., must be summarized on the SAE form. 
Follow -up informati
on about a previously reported SAE must also be reported within 
[ADDRESS_258824] is hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_42869], it is the investigator ’s 
responsibility to contact [CONTACT_42933][INVESTIGATOR_42870] -relevant i
nformation and 
documentation. 
The expectedn
ess of an adverse reaction is determined by [CONTACT_215256] (RSI) section provided in the most recent version of the IB. Any SAE that  is 
assessed as related and unexpected against the RSI is known as a SU SAR and must be 
ACT -[ADDRESS_258825] 2016 , page 85/[ADDRESS_258826]  2016 -000827 -16 
Doc No D -16.394 
 
 
reported by [CONTACT_215257] (including the EudraV igilance 
database if the study is conducted in Europe), IECs/IRBs and investigators. 
9.3 Study safety monitoring  
Clinical study safety information (AEs, SAEs, laboratory  values, ECGs, vital signs, and 
project -specific e
xaminations as required) is monitored and reviewed on a continuous 
basis by [CONTACT_208248] (in charge of ensuring subjects ’ safety as well as data 
quality). In addition, an IDMC and an I SB are monitoring safety data [see Sectio n 3.4]. 
10 STATISTICAL METHODS 
All statistical analyses will be conducted by [CONTACT_215258].  
A statistical analysis plan ( SAP) will provide full details of the analyses, data displays, 
and algorithms to be used for data derivations. 
This study is
 using a Latin  square crossover  design, hence each subject is to receive each 
treatment (including placebo). All analyses described in this section are based on the 
assumption that there is no carry -over effect  [see S
ection  3.2]. 
In the belo
w section the term Days [ADDRESS_258827] been assigned to a study 
treatment.  
 Full Analysis Set  10.1.3The Full Analysis Set (FAS) includes all subjects from the r andomized analysis set who 
received any  dose of study treatment. 
In order to adhe
re to the intention -to-treat princip
le: 
• subjects wi
ll be evaluated according to the study treatment they have been assigned to 
(which may be different from the study treatment they actually receive),  
• all available data are taken into account.  
ACT -[ADDRESS_258828] 2016 , page 86/[ADDRESS_258829]  2016 -000827 -16 
Doc No D -16.394 
 
 
 Modified FAS  10.1.4
Modified FAS (mFAS) includes all patients from the FAS and who have a t least one 
WASO assessment at Baseline and at least one at Days 1 and 2 of any given t reatment 
period. 
 Per-protocol Analysis Set 10.1.5
The Per -Protocol An
alysis Set (PPS) comprises all subjects from the mFAS, who have 
two consecutive WASO values at both B aseline and Days [ADDRESS_258830] , before breaking the treatment 
blind. 
 Safety Set  10.1.6
The Safety Set (SS) includes all randomized subjects who received at least one dose of 
study tr eatment. Subjects will be evaluated according to the actual dose they received, 
which may differ from the randomly assigned dose. 
 PK Analysis Set 10.1.7The PK Analysis Set includes all subjects in the  SS who have at least one PK sample 
collected after initiation  of study drug. 
 Usage of the analysis sets 10.1.8The primary efficacy analysis will be performed on the mFAS based on dose as 
randomized. Secondary and exploratory efficacy endpoint analyses will also be performed on the mFAS, while FAS and PPS will be considered for sensitivity analyses.  
Safety analyses will be performed on the SS based on actual dose received.  
Subject listings will be based on the SS, unless otherwise specified. Subject disposition will be described for the Screened and Randomized Analysis Set.  
Table [ADDRESS_258831] 2016 , page 87/[ADDRESS_258832]  2016 -000827 -16 
Doc No D -16.394 
 
 
Table 4 Usage of analysis datasets  
 Screened  Randomized  FAS  mFAS  PPS SS PK set  
Patient disposition  X X      
Baseline and disease 
characteristics   (x) X (x) (x)  (x) 
Previous and concomitant 
medication       X  
Study drug exposure      (x) X  
Primary efficacy endpoint    (x) X (x)   
Secondary and exploratory 
efficacy endpoints    (x) X (x)   
Safety and tolerability       X  
PK data       X 
Note: X: main analysis, (x): sensitivity analysis to be conducted only if >  10% difference of set size with set used for 
main analysis.  
FAS = Full Ana
lysis Set; mFAS = modified Full Analysis Set; PK = pharmacokinetic; PPS = Per -protocol S
et, SS = 
Safety Set.  
 
10.[ADDRESS_258833] two values collected during the screening phase prior to randomization.  
 Primary efficacy variable 10.2.1
Efficacy variables are described in Appendix 10. 
The primary eff icacy endpoint relates to sleep maintenance and is assessed through the 
absolute change in minutes of WASO from Baseline
9 to Days 1 and 210. 
WASO is defined in S ection  6.1.1. 
                                                 
9 ‘Baseline’ is the mean of the two  PSG nights during run -in period (V2) . 
10 ‘Days 1 and 2’  is the mean of the corresponding two  PSG treatment nights  for a given treatment period.  
ACT -[ADDRESS_258834] 2016 , page 88/[ADDRESS_258835]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS] Missing values  
No imputation will be per formed for missing WASO values. However, if the proportion 
of missing values is significant (e.g., > 10%) , sensitivity analyses will be considered to 
assess the influence on the primary analysis . 
If one of the t wo values is missing either at B aseline or at Days 1 and 2, the only 
available value will be used for this time point; however, for the PPS analysis, onl y 
assessments with two values at each time point will be considered.  
 Secondary efficacy variable 10.2.2
The secondary efficacy endpoint relates to sleep  initiation and is assessed through the 
absolute change from Baseline11 to Days 1 and 212 in mean  LPS.  
LPS is defined in S ection 6.1.2. 
[IP_ADDRESS] Missing values  
Similarly to  the primary endpoint, no imputation is  to be performed ; however, sensitivity 
analyses will be considered as  necessary . 
 Other exploratory efficacy variables  10.2.3Other exploratory efficacy endpoints include:  
• sWASO,  WASO overnight 
• sLSO 
• TST and sTST 
• SQ 
• Sleep stage S1, S2 , SWS and REM 
• Shifts from S2, SWS or REM to S1 or wake 
• Wake time during sleep  
• Frequency
 of awakenings as measured by [CONTACT_215238] -reported  
• SE (defined as
 100 × (TST / time in bed)  
• Next -day performa
nce 
For each vari
able, multiple aspects will be considered in the analysis:  
[IP_ADDRESS] Sleep -maintenance endpoint 
• WASO overnight (by [CONTACT_215259]). 
• sWASO absolute change from Baseline13 to Days 1 and 214. 
                                                 
11 ‘Baseline’ is the mean of the two  PSG nights during run -in period (V 2). 
12 ‘Days 1 and 2’  is the mean of the corresponding two PSG treatment nights  for a given treatment period.  
ACT -[ADDRESS_258836] 2016 , page 89/[ADDRESS_258837]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS] Sleep-initiation  endpoint 
• sLSO absolute change from Baseline13 to Days 1 and 214. 
[IP_ADDRESS] Total sleep time endpoi nt 
• TST absolute change from Baseline11 to Days 1 and 212. 
• sTST absolute change from Baseline13 to Days [ADDRESS_258838] is the am
ount of actual  sleep  time (time spent in epochs scored as non -wake), as 
d
etermined by [CONTACT_63175]. sTST is the self -reported t
ime spent asleep, as reported in the sleep 
diary. 
[IP_ADDRESS] SQ 
• Change f
rom Baseline13 to Days 1 and 214 in SQ . 
SQ is the sleep quality as determined by [CONTACT_215260].   
[IP_ADDRESS] Sleep architecture 
• Mean15 duration and mean percent of TST of each sleep stage (S1, S2, SWS and 
REM) for the whole night, and for each quarter of the night. 
• Mean15 latency to each sleep stage (S1, S2, SWS, and REM).  
[IP_ADDRESS] Sleep continuity  
• Mean15 number and frequency of shifts from S2, SWS or REM to S1 or wake for the 
whole night. 
• Mean15 wake time during sleep: time spent in epochs scored as wake between LPS 
and last epoch not scored wake for the whole night. 
• Mean15 frequency of awakenings: number of awakenings between first epoch and last 
epoch not scored wake for the whole night, by [CONTACT_215261].  
• Change fr
om Baseline13 to Days 1 and 214 in self -reported number of awakenings 
(sNA).  
[IP_ADDRESS] SE 
• Change fr
om Baseline11 to Days 1 and 212. 
SE is defined as 100 ×  (TST [min utes] / time in bed [min utes]). 
                                                                                                                                                 
13 ‘Baseline’ is the mean value of the sleep diary entries during run -in period (V 2). 
14 ‘Days 1 and 2’  is the mean value of the corresponding sleep diary entries for a given treatment period.  
15 ‘Mean ’ calculated based on two  PSG nights for a given treatment period.  
ACT -[ADDRESS_258839] 2016 , page 90/[ADDRESS_258840]  2016 -000827 -16 
Doc No D -16.394 
 
 
[IP_ADDRESS] Next -day performance 
• Change fr
om Baseline13 to Days 1 and 214 in next -day performance assessed by 
[CONTACT_215262] V
AS assessing morning sleepi[INVESTIGATOR_008], daytime alertness a nd daytime 
ability to function. 
 Safety variabl
es 10.2.4
Safety analysis will be conducted on the SS, and will include all safety data collected up 
to 30 days after study drug discontinuation. 
[IP_ADDRESS] Adverse events  
An AE is defined as any event  that is recorded on the AE eCRF module regardless of the 
onset date.  
TEAEs for a 
given treatment group  are those with onset date/time ≥  start date/time of 
double -blind study tr
eatment of each treatment period  and ≤ 5 days after end of study 
treatment  of each treatment period, and ≤  [ADDRESS_258841]  [see Section 6.2], with onset 
prior to study 
treatment dose that  worsened during the treatment phase will also be reported as TEAE s. 
The handling of missing or incomplete dates/time of AEs and assessments will be 
described in the SAP. 
[IP_ADDRESS] Laboratory data 
Laboratory an
alyses are based on data received from the central laboratory. All 
transferred central laboratory data are taken into account regardless of whether they 
correspond to scheduled or unscheduled assessments. Baseline laboratory test refers to the latest laboratory test performed prior to start of double
-blind study tr
eatment.  
[IP_ADDRESS] ECG  
• Treatment -emergent EC
G abnormalities from V3 until EOT.  
• Change from
 Baseline (V2, seco nd morning) to the seco nd morning after the PSG 
nights at V3, V4, V5, V6 and V7 in ECG parameters.  
[IP_ADDRESS] Other safety parameters of interest  
Change from 
Baseline (mean of the two PSG nights at V2, run -in period) to D
ays 1 and 2  
(mean of the two  PSG treatment nights)  of each treatment period  in: 
• KSS perfor
med in the morning, 30–60 minutes after lights on. 
• DSST performed in the morning, 30–60 minutes after lights on. 
• SDS performed in the morning, 30–[ADDRESS_258842] 2016 , page 91/[ADDRESS_258843] severe suicidal ideation and suicidal behavior s according to the 
C-SSRS for each treatment period. 
[IP_ADDRESS] Vital signs  
Change from Baseli
ne (mean of the first and second morning values  after the two PSG 
nights at V2, run -in period) to the Days
 1 and 2 ( mean of the first and second morning 
values  after the two  PSG treatment nights) for a given treatment period in vital signs 
(systolic and diastolic BP, pulse rate and body temperature). 
[IP_ADDRESS] Body w eight  
Change fr
om B aseline ( V1) to the second morning  after the PSG nights at V7  in body 
weight.  
  Other variables 10.2.[ADDRESS_258844] -541468 (~9–[ADDRESS_258845] -dose) at V3, V4, V5, V6 and
 
V7. 
10.[ADDRESS_258846]  
[see Sect
ion 3.2]. The duration of the wa
shout is considered sufficient for  all doses of 
ACT -541468. 
The i ncidence and patter
n of missing values will be explor ed in order to evaluat e the 
possible impact on the planned analyses.  
 Analysis of the primary efficacy variable 10.3.2
[IP_ADDRESS] Hypotheses and statistical model  
Subjects w ill be randomized 1:1:1:1:1 to five  different sequences of five study treatments 
according to a Latin square design [ see Table 1]. The five  study tre
atments are oral fixed 
doses of AC -541468 (5, 10, 25, 50 mg) and place
bo. 
The study is using
 the generalized Multiple Comparison Procedure – Modeling 
(MCP -Mod) approach [ Bretz  2005, Pi[INVESTIGATOR_17872] 2006,
 Pi[INVESTIGATOR_17872] 2014 ], which combines a 
mu
ltiple -comparison proced
ure to assess the efficacy of the drug versus placebo and a 
modeling step to further identify the dose that is most likely to provide the expected level 
of efficacy (based on the primary efficacy endpoint).  
ACT -[ADDRESS_258847] 2016 , page 92/[ADDRESS_258848]  2016 -000827 -16 
Doc No D -16.394 
 
 
The generalized approach is appropriate for this study design where each patient receives 
different doses in a sequence. A univariate dose -response relationshi
p is modeled based 
on the mean change from baseline in WASO at each dose [see Section [IP_ADDRESS]] . This 
approach has b
een qualified by [CONTACT_215263] “an efficient statistical methodology for 
model- based design and analysis of phase II dose finding studies under model 
uncertainty ” [EMA 2013].  
The maximum mean re
duction in WASO from baseline to Day s [ADDRESS_258849] -541468 dose is assumed to be 25 mi
nutes (standard deviation = 40 minutes) larger 
than placebo. 
The null hypothesis of 
an absence of a dose -response relationship  fo
r change from 
baseline in WASO will be tested at a two -sided significance
 level of 5% against the 
alternative hypothesis of existence of a dose response. 
Dose  selectio n to be used
 in future clinical trials will be done in consideration of the  
statistical results and  clinically meaningful criteria.  
[IP_ADDRESS] Handling of missing data 
For any given visit , if one of the two WASO values is missing, the available value will be 
used as the mean for the given treatment period. If both values are missing, no imputation will be considered. Further imputation rules may be defined in the SAP. 
[IP_ADDRESS] Main analysis 
The primary statistical analysis will be performed on the mFAS.  
The absolute change i
n WASO will be analyzed using the MCP -Mod approach 
[Bretz  2005, Pi[INVESTIGATOR_17872] 2006 ] using a set of multip
le contrast tes ts (MCTs) to establish the 
existence of a dose response that  is based on a pre -specified set of  dose -response m odels 
describ
ing the potential dose -response relationsh
ip. 
The following  pre-defined dose-response models are co
nsidered : one linear, and three  
Emax models. Figure  2 shows  the candidate dos e-response curves for t he mean reduction 
from baseline in WASO. 
The analysis will
 be performed using the R -package DoseFinding [Bornkamp 2016 ]. For 
each candidate mod
el, a t -statistic is der
ived based on a linear combination of the mean 
response estimates per individual dose  and using optimal contrast coefficients 
corresponding to the candidate model . The mean response estimates are the least -squares 
mean (for cha
nge from baseline in WASO) of each dose group estimated by [CONTACT_6486] a 
mixed model adjusted for baseline WASO, with dose group and period as fixed effects, 
and subject as a random effect.  A dose -response relation
ship is demonstrated if at least 
one of the four MCTs has an adjusted p -value < 0.05. The best -fitting model based on
 
ACT -[ADDRESS_258850] 2016 , page 94/[ADDRESS_258851]  2016 -000827 -16 
Doc No D -16.394 
 
 
 Analysis of secondary efficacy variable 10.3.3
Simila rly, an M
CP-Mod -based analy
sis will be conducted on the secondary endpoint. 
Treatment ef
fects on the secondary efficacy endpoint will also  be assessed using a mixed 
model similar as for the primary analysis.  
 Analysis of other exploratory efficacy variables  10.3.4
Descriptive statistics will be provided for all the exploratory  variables , either as  
frequency and percentage for categorical variables or using  descriptive statistics for 
continuous variables. 
Further exploratory analysis will be conducted to assess the relationship of the changes 
between the perceived efficacy (subjective measures) and the objective measures from PSG.  
Additional exploratory analysis will be described in full detail in the SAP.  
[IP_ADDRESS] Subgroup analyses 
Subgroup analyses may be considered and will be described in the SAP. 
 Analysis of the safety variables 10.3.5
All safety analyses will be performed on the SS, by [CONTACT_2715] , using descriptive statistics. All 
safety data will be listed, with flags for quantitative abnormalities.  
Observations and assessments (e. g., AEs, laboratory data) occurring within a treatment 
period (from the time of dosing to the time immediately prior to the next dose) will be 
assigned to the dose taken in that period. 
[IP_ADDRESS] Analysis of safety and tolerability endpoints 
Safety and tolerability quantitative endpoints will be summarized using descriptive 
statistics (mean, standard deviation, median, first  and third  quartiles, minimum, and 
maximum) while frequency counts and proportions will be used for categorical data. 
Unless stated otherwise, percentages will be computed on the  number of subjects who 
received the given dose. 
[IP_ADDRESS] Adverse events  
AEs and SAEs in subjects who were screened but not part of the SS will be listed.  
The number and percentage of subjects experiencing TEAEs and SAEs will be tabulated by [CONTACT_215206]: 
• MedDRA  system organ class (SOC) in alphabetical order and individual preferred 
term within each SOC, in descending order of incidence in the highest dose group. 
ACT -[ADDRESS_258852] 2016 , page 95/[ADDRESS_258853]  2016 -000827 -16 
Doc No D -16.394 
 
 
• Frequency of subjects with events coded with the same preferred term, in descending 
order of incidence in the highest dose group. 
TEAEs, AEs of special interest and SAEs will be tabulated as described above by [CONTACT_78621]. AEs leading to premature discontinuation of the study treatment and AEs with outcome death will be summarized as described above.  
AEs and SAE
s with onset between screening and first day of double -blind study 
trea
tment will also be summarized.  
Listin gs will
 be provided for all reported AEs, including SAEs. In addition, separate 
listings will be provided for SAEs, for AEs leading to premature discontinuation of study treatment, and for AEs with outcome death. 
[IP_ADDRESS] Laboratory variables 
Descriptive summary statistics by [CONTACT_215264], in both hematology and blood chemistry laboratory tests. All 
central laboratory data will be  taken into account regardless of whether they correspond 
to scheduled or unscheduled assessments. Marked laboratory abnormalities [ Appendix 1 ] 
will b e summarized for each laboratory variable by [CONTACT_215208].  
The number and per
centage of subjects with treatment -emergent labo
ratory abnormalities 
will be tabulated by [CONTACT_2715]. 
[IP_ADDRESS] ECG  
Incidence of
 clinically abnormal ECG on double -blind study tr
eatment as well as 
treatment -emergent EC
G abnormalities will be tabulated (frequency and percentage)  by 
[CONTACT_2715].  
On-treatment ch
ange in ECG parameters will be described using descriptive statistics.  
[IP_ADDRESS] Vital signs  
Ch
ange will be summarized  by [CONTACT_2715]. 
[IP_ADDRESS] Other safety parameters of interest  
Change from 
Baseline (mean of the two PSG nights at V2, run -in period) to D
ays 1 and 2  
(mean of the two  PSG treatment nights) in KSS, DSST, and SDS will be summarized  
by [CONTACT_2715]. 
The incidence of
 most severe suicidal i deation and suicidal behaviors according to the 
C-SSRS will be summarized  by [CONTACT_2715]. 
ACT -[ADDRESS_258854] 2016 , page 96/[ADDRESS_258855]  2016 -000827 -16 
Doc No D -16.394 
 
 
All scales analyses will be performed according to their respective manual and 
interpretation g uide. 
[IP_ADDRESS] Exposure- safety analysis  
The exposure -safety re
lationship will be explored using C 9-10h (plasma concentration of 
ACT -541468 the morning of t
he second PSG night at V3, V4, V5, V6 and V7) and will 
be based on the PK set. Safety parameters considered for this analysis will include 
selected AEs (e.g. somnolence), changes fro m baseline in DSST and other parameters as 
relevant.  
Further deta
ils will be provided in the SAP. 
[IP_ADDRESS] Pharmacokinetic 
Plasma concentr
ations of ACT -[ADDRESS_258856] deviation, minimum, maximum, and 
median.  
10.4 Interim analyses  
No formal interim analysis will be performed  for determining whether to stop (or modify) 
the study  early  (i.e. no hypothesis testing will be conducted at interim). Therefore, no 
adjustment for multiple testing is required. This study includes an IDMC and ISB that 
will assess safety of ACT -541468 on a regular b
asis as per IDMC and ISB charters, 
respectively.  
Safety and effi
cacy data supporting the review by [CONTACT_215265]. 
10.5 Sample size  
The following sample -size calculatio ns ar e based on MCP -Mod methodology 
[Pi[INVESTIGATOR_17872] 2006] . Com
putations were performed in R version 3.1.[ADDRESS_258857] -541468 dose is 25 minute
s (standard deviation = 40 minutes) larger than with 
placebo, and values from 8% of subjects are not available for analysis, a total sample size 
of approximately 50 (i.e., 10 subjects per sequence allocated in a 1:1:1:1:1 ratio) provides 
between 8 9–92% power  (power is 90% when averaged over all candidate models 
[Figure  2]) to rejec
t the null hypothesis of no dose  response at a  5% two-sided 
significa
nce le vel, while t he alternative hypothesis is that a dose -response rela
tionship 
exists.  
ACT -[ADDRESS_258858] 2016 , page 97/[ADDRESS_258859] deviation in WASO across all arms is expected to be no 
more than 40 minutes. The sample size is conservative, since a correlation of zero (and 
non-negative)  i
s assumed between assessments across dose within the same subject.  
Assuming the
 maximum mean reduction in WASO is considered to be 20 minutes larger 
than with placebo, a sample size of 71 subjects (with no dropout)  are required. This 
number decreases  to [ADDRESS_258860]
acebo nor to 
provide a certain precision in estimation of a given ta rget dose. 
11 DATA HANDLING  
11.1 Data collection 
The investigator/delegate is responsible for ensuring the accuracy, completeness and timelines of the data reported. All source documents are recommended to be completed in a neat, legible manner to ensure accurate interpretation of the data. Data reported in the 
eCRF derived from source documents must be consistent with the source documents. 
eCRF data wil
l be captured via electronic data capture using the Rave system provided by 
[CONTACT_70598], Inc., a web -based tool. The i
nvestigator and site staff  will be trained 
to enter and edit the data via a secure network, with secure access features (username, password, and identification – an electronic password system). A complete electronic 
audit trail will be maintained. The investigator/delega te will approve the data 
(i.e., confirm the accuracy of the data recorded) using an electronic signature (ref. to US 21 CFR Part 11).  
Entries re
corded by [CONTACT_42918] -held device (
i.e., sleep di ary, VAS, ISI, 
C-SSRS, KSS, SDS) and on paper (i.e., DSST) are considered source data. Site staff  
will review and ensure completeness and readability of the subjects’ entries.  
Subject  screen
ing and enrollment data will be completed for all subjects (i.e., eligible and 
non-eligible) thr
ough the IRT system and e CRF.  
For each s
ubject enrolled, regardless of study treatment initiation, a n eCRF must be 
completed and signed by [CONTACT_093]/delegate. This also applies to those subjects who fail to complete the study. If a subject withdraws from the study, the reason must be noted on the e CRF.  
ACT -[ADDRESS_258861] 2016 , page 98/[ADDRESS_258862]  2016 -000827 -16 
Doc No D -16.394 
 
 
11.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On e CRFs 
or other documents (e.g., documents attached to SAE forms) submitted to Actelion and 
any CROs, subjects must be identified only by [CONTACT_209017] n ever by [CONTACT_215266] , hospi[INVESTIGATOR_42871], or any other identifier. The investigator/delegate must keep a 
subject identification code list at the site, showing the screenin g/randomization number, 
the subject ’s name, date of birth, and address or any other locally accepted identifiers. 
Documents identifying the subjects (e.g., signed ICFs) must not be sent to Actelion, and 
must be kept in strict confidence by [CONTACT_093] /delegate.  
11.[ADDRESS_258863] status at any time  point during the course of the 
study.  
While enter
ing the data, the investigator/delegate will be instantly alerted to data queries 
by [CONTACT_42940]. Additional data review will be performed by [CONTACT_215267]. If discrepant data are detected, a query specifying the problem and requesting clarification will be issued and visible to the investigator/delegate via the e CRF. All 
elect ronic queries visible in the system either require a data correction (when applicable) 
and a response from the investigator/delegate to clarify the queried data directly in the eCRF, or simply a data correction in the e CRF. The investigator/delegate must, on 
request, supply Actelion with any required background data from the study documentation or clinical records. This is particularly important when errors in data transcription are suspected. In the case of  health author ity queries, it is also necessary to  
have access to the complete study records, provided that subject confidentiality is protected.  
This process will continue until database closure. 
Laborator
y samples  and ECG recordings  will be processed through a central laboratory . 
PSG data will be read by a central reviewer. Patient -reported out
comes (PRO) will be 
collected on hand -held device
s. All the  results of the laboratory analyses, ECGs, PSG 
data and PRO will be electronically sent to Actelion.  
If local l
aboratory data is obtained as may be required per protocol in certain instances, it 
must be entered in the eCRF by [CONTACT_14523].  
AEs are coded according to the latest Medical Dictionary for Regulatory Activities  
(MedDRA ) used by [CONTACT_180494]. 
ACT -[ADDRESS_258864] 2016 , page 99/[ADDRESS_258865]  2016 -000827 -16 
Doc No D -16.394 
 
 
After the database has been declared complete and accurate, the database will be closed. 
Any changes to the database after that time may only be made as described in the appropriate Actelion QS documents . After database closure, the investigator will receive 
the eCRFs of the subjects of his/her site (i ncluding all data changes made) on electronic 
media or as a paper copy.  
12 PROCEDURES AND GOOD CLINICAL PRACTICE  
12.1 Ethics and Good Clinical Practice 
Actelion staff and the investigators will ensure that the study is conducted in full 
compliance with ICH -GCP Gu ideline
s, the principles of the ‘ Declaration of Helsinki ’, 
and with the laws and regulations of the country in which the study is conducted. 
12.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any relate d document(s) provided to the 
subject (such as the I CF) to an IEC/IRB. Approval from the committee/board must be 
obtained before starting the study, and must be documented in a dated letter to the investigator, clearly identifying the study, the documents reviewed, and the date of approval. 
Modifications made to the protocol or the I CF after receipt of the approval must also be 
submitted as amendments by [CONTACT_42942]/IRB in accordance with local 
procedures and regulations [see Section 12.6].  
A list of members participating in the IEC/IRB meetings must be provided, including the names, qualifications, and functions of these members. If t hat is not possible, the attempts 
made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation.  
If a member of the study staff was present during an IEC/IRB meeting, i t must be clear 
that this person did not vote. 
12.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according 
to ICH -GCP and Decl
aration of Helsinki guidelines and local regulations from each 
individual participating in this study. In European countries the informed consent must be 
obtained by a physician. The investigator/delegate must explain to subjects that they are completely free to refuse to enter the study, or to voluntarily withdraw from the study at any time for any reason without having to provide any justification. Special attention 
shall be paid to the information needs of specific subject populations and of individual subjects, as well as to the methods used to give the information. Adequate time sha ll be 
given for the subject to consider his or her decision to participate in the study and it shall 
ACT -[ADDRESS_258866] 2016 , page 100/[ADDRESS_258867] has understood the information (e.g., by [CONTACT_215268]). 
The ICF will be provided in t he country local language(s).  
Site staff authorized to participate in  the consent process and/or to obtain consent from 
the subject will be listed on the Delegation of Authority ( DoA) form supplied by 
[CONTACT_180494]. A study physician must always be involved in the consent process.  
The subject
 and authorized site staff  listed on the D oA form supplied by [CONTACT_215269], personally date, and time (if the first study -mandated pro
cedure is to be performed 
on the same day informed consent is obtained) the ICF before any study -related 
proce
dures (i.e., any procedures required by [CONTACT_760]) begin.  
A copy of t
he signed and dated ICF is given to the subject; the original  is filed in the site 
documentation. The informed consent process must be fully documented in the subject ’s 
medical records. This must include at a minimum the study reference, the subject 
number, the date and, if applicable, time when the subject was first introduced to the study, the date and, if applicable, time of consent, who participated in the consent discussion, who consented the subject, and any additional person present during the consent process (e.g., subject ’s family member[s]), and the information that a copy of the 
signed ICF was given to the subject. 
12.4 Compensation to subjects and investigators 
Actelion provides insurance in order to indemnify (with both legal and financial coverage) the investigator/site against claims arising from the study, except for claims that arise from malpractice and/or negligence.  
The compensa
tion of the subject in the event of study -related inju
ries will comply with 
applicable regulations. 
12.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the IEC/IRB and/or the regulatory authority
-approved vers
ion of the protocol and must not implement any 
deviation/change from the protocol, except when deviation is necessary to eliminate an immediate hazard to the subject.  
If a protoc
ol deviation occurs, the investigator/delegate will inform Actelion or its 
representative in a timely manner. The investigator/delegate must document and explain any deviation from the approved protocol. Deviations considered to be a violation of ICH
-GCP must be
 reported to the IEC/IRB and regulatory authorities according to 
Actelion or (overruling) local requirements. 
ACT -[ADDRESS_258868] 2016 , page 101/[ADDRESS_258869]  2016 -000827 -16 
Doc No D -16.394 
 
 
All protocol deviations will be reported in the CSR. IECs/IRBs will be provided with 
listings of protocol deviations as per local requirements. 
12.[ADDRESS_258870] be submitted to the IEC/IRB and regulatory authorities, according to their requirements. 
12.7 Essential documents and retention of documents 
The investigator/delegate must maintain adequate records necessary for the reconstruction and evaluation of the study. A number of attributes are considered of universal importance to source data and the records that hold those data. These include that the  data and records are accurate, legible, contemporaneous, original (or certified 
copy), attributable, complete, consistent, enduring, and available when needed. 
These records are to be classified into two different categories of documents: ISF and 
subjects ’ source documents. 
These records must be kept by [CONTACT_180533] ’s requirements (i.e., as specified in the clinical study agreement) and national 
and/or international regulations, whichever would be the  longest period. If the 
investigator cannot guarantee this archiving requirement at the site for any or all of the documents, special arrangements, respecting the data confidentiality, must be made between the investigator and Actelion to store these documents outside the site, so that they can be retrieved in case of a regulatory inspection. No study document should be destroyed without prior written approval from Actelion. Should the investigator wish to assign the study records to another party, or move them to another location, Actelion must be notified in advance. 
If the site is using an electronic/computerized system to store subject medical records, it 
can be used for the purpose of the clinical study if it is validated (as per [ADDRESS_258871]) and if the CRA has been provided personal and restricted access to study subjects only, to verify consistency between electronic source data and the eCRF 
during monitoring visits.  
If the site is
 using an electronic/computerized system to store subject medical records but 
it could not be confirmed that the system is validated or if the CRA could not be provided access to the system, the site is requested to print the complete set of source data needed for verification by [CONTACT_2689]. The print
-outs must be
 numbered, stapled together with a 
coversheet, signed and dated by [CONTACT_093]/delegate to confirm that these certified copi[INVESTIGATOR_215182]. The 
ACT -[ADDRESS_258872] 2016 , page 102/[ADDRESS_258873]’s medical records or with the subject’ s eCRF.  
In order to verify that the process the site uses to prepare certified copi[INVESTIGATOR_42874], the CRA must be able to observe this process and confirm that the comparison of the source documents and the certified copy did not reveal inconsistencies. The CRA does not need to verify this process for all data of all subjects but at least for some of them (e.g., first subject; regular check during the study of critical data like inclusion/exclusion criteria, endpoints for some subjects) as per Actelion’ s instructions. If it were not possible for the 
CRA to observe this process, it would not be possible to rely on the site ’s certified copi[INVESTIGATOR_42875].  
12.8 Monitoring 
Prior to study start, a site initiation visit (SIV) will be performed after the required essential study documents are approved by [CONTACT_180494]. The study treatment will be shipped to the site upon approval of the required essential documents. 
The PI [INVESTIGATOR_215183]. Site  Information Tech nology support should also be 
available during the SIV.  
The SIV mu
st be completed before the site can start the screening of study subjects. 
Following the SIV, a copy of the completed initiation visit report and follow -up letter 
wi
ll be provided to the PI [INVESTIGATOR_42876]. 
During the
 study, the CRA will contact [CONTACT_42947], 
on request, to have access to study facilities and all source documents needed to verify 
adherence to the protocol and the completeness, consistency, and accuracy of the data being entered in the eC RFs and other protocol
-related doc
uments. Actelion monitoring 
standards require full verification that informed consent has been provided, verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety, and tolerability endpoints. Additional checks of the consistency of the source data with the e CRFs will be performed according to the 
study
-specific mo
nitoring guidelines. The frequency of the monitoring visits will be 
based on subject rec ruitment rate and critical data -collection time
s. 
The PI [INVESTIGATOR_215184] e CRF is completed after a subject ’s visit (site visit or 
telephone call)  and that all requested subject files (e.g., ICFs, medical notes/charts, other 
documentation verifying the  activities conducted for the study) are available for review 
by [CONTACT_2689]. The required site staff  must be available during monitoring visits and allow 
adequate time to meet with the CRA to discuss study -related iss
ues. 
ACT -[ADDRESS_258874] 2016 , page 103/[ADDRESS_258875]  2016 -000827 -16 
Doc No D -16.394 
 
 
The investigator agrees to cooperate with the CRA(s) to ensure that any issues detected in 
the course of these monitoring visits are resolved. If the subject is hospi[INVESTIGATOR_42878] a hospi[INVESTIGATOR_42869], the investigator is responsible for contact[CONTACT_42948][INVESTIGATOR_215185], in accordance with local regulations. 
A close -out visit will be
 performed for any initiated site when there are no more active 
subjects and all follow -up issues ha
ve been resolved. In case a site does not enroll any 
subjects, the close -out visit ma
y be performed prior to study database closure at the 
discretion of Actelion. 
12.[ADDRESS_258876] be kept by [CONTACT_208289], ICH
-GCP, as w
ell as instructions from Actelion. If the site needs to transfer 
the ISF to another location and/or if site facility can no longer store the ISF, the PI [INVESTIGATOR_208164].  
If the PI w
ill change, or if the site will relocate, the CRA must be notified as soon as 
possible. 
12.10  Audit  
Actelion ’s Global Quality Man agement  representatives may audit the investigator site 
(during the study or after its completion). The purpose of this visit will be to determine 
the investigator ’s adherence to ICH -GCP, the prot
ocol, and applicable regulations; 
adherence to Actelion ’s requirements (e.g., SOPs) will also be verified. Prior to init iating 
this audit, the investigator will be contact[CONTACT_180536] a time for the audit.  
The investi
gator and site staff  must cooperate with the auditor(s) and allow access to all 
study documentation (e.g., subject records) and facilities. 
12.11  Inspec tions 
Health authorities and/or IEC/IRB may also conduct an inspection of this study (during 
the study or after its completion) at the site.  
ACT -[ADDRESS_258877] 2016 , page 104/[ADDRESS_258878]  2016 -000827 -16 
Doc No D -16.394 
 
 
Should an inspection be announced by a health authority and/or IEC/IRB, the investigator 
must immediately inform Ac telion (usually via the CRA) that such a request has been 
made.  
The investigator and site staff must cooperate with the inspector(s) and allow access to all 
study documentation (e.g., subject records) and study facilities. 
12.[ADDRESS_258879] the key elements of this protocol and the summary of results on Actelion ’s Clinical Trial Register and within the required timelines on publically 
accessible databases (e.g., clinicaltrials.gov, EU database), as required by [CONTACT_42951]. 
Study re
sults will be documented in a CSR that will be signed by [CONTACT_215270] (or PI [INVESTIGATOR_208166] -center stu
dies).  
In accordan
ce with the Good Publication Practices and ethical practice, the results of the 
study will be submitted for publication in a pe er-reviewed j
ournal. Study results can be 
submitted for presentation at a congress before submission to a peer -reviewed j
ournal. 
The Trial  Coor
dinating Investigator and the Steering Committee, if any, will have the 
opportunity to review the analysis of the  data and to discuss the interpretation of the 
study results with Actelion staff  prior to submission to a peer -reviewed j
ournal or 
presentation at a congress.  
Authorship wi
ll be determined in accordance with the International Committee of Journal 
Editors c riteria, and be based on:  
• substantial contributions to the conception or design of the study, or the acquisition, 
analysis, or interpretation of data; and 
• drafting of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and 
• agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved. 
The list of authors of any publication of study results may include representatives of Actelion and will be determined by [CONTACT_11402].  
Any study -related pu
blication written independently by [CONTACT_215271] [ADDRESS_258880] alterations and/or deletions for the sole purpose of protecting its confidential information 
ACT -[ADDRESS_258881] 2016 , page 105/[ADDRESS_258882]  2016 -000827 -16 
Doc No D -16.394 
 
 
and/or patent rights. Neither the institution nor the investigator should permit publication 
during such a review period. 
Actelion ’s Policy on Scientific Publications can be found at: 
http://www.actelion.com/documents/corporate/policies -charters /policy -scientific -
publications.pdf. 
ACT -[ADDRESS_258883] 2016 , page 106/[ADDRESS_258884]  2016 -000827 -16 
Doc No D -16.394 
 
 
13 REFERENCES 
[aasmnet.org] American Academy of Sleep Medicine (AASM) Standards and Guidelines 
for the Practice of Sleep Medicine, regularly updated  [accessed on 10 June 2016]. 
Available from : http://www.aasmnet.org . 
[ACT -541468 IB] Invest
igator ’s Brochure for ACT -[ADDRESS_258885] version 3. Actel ion Pharmaceuticals Ltd May 2016. 
[Agostini
 2004] Agostini JV, Han L, Tinetti ME. The relationship between number of 
medications and weight loss or impaired balance in older adults. J Am Geriatr Soc 
2004;52(10):1719 -1723. 
[Ambien® USPI] Ambien® (zolpi[INVESTIGATOR_6730]) US Package Insert. [LOCATION_002] Food and Drug 
Administration full prescribing information. Revised 2/2008. 
[Ancoli -Israel 2009]
 Ancoli -Israel S
. Sleep and its disorders in aging populations. Sleep 
Med 2009;[ADDRESS_258886] 1:S7–11. 
[Avidan 2005] Avi
dan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD. 
Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005;53(6):955
-62. 
[Belsomra® USPI] Belsomra® (suvorexant) US Package Insert. [LOCATION_002] Food and 
Drug Administration full prescribing information. Revised 8/2014. 
[Blackwell
 2006] Blackwell T, Yaffe K, Ancoli -Israel S, S
chneider JL, Cauley  JA, 
Hillier TA, et al. Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci  
2006;61(4):405–10. 
[Bornkamp 2016
] Bornkamp B, Pi[INVESTIGATOR_17872] J, Bretz F. Documentation of the R Package 
‘DoseFinding’. 2016, Version 0.9–14.  
[Bretz  2005] B
retz F, Pi[INVESTIGATOR_144676], Branson M. Combining multiple comparisons and 
modeling techniques in dose -response st
udies. Biometrics. 2005;61(3):738–48. 
[Buscemi
 2007] Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospi[INVESTIGATOR_28947] M, 
et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta
-analysis
 of RCTs. J Gen Intern Med 2007;22(9):1335–50. 
[Carney 
2012] Carney CE, Buysse DJ, Ancoli -Israel S
, Edinge r JD, Krystal AD, 
Lichste in KL  The consensus sleep diary: standardizing prospective sleep self -
monitoring. S
LEEP 2012;35(2):287–302. 
ACT -[ADDRESS_258887] 2016 , page 107/[ADDRESS_258888]  2016 -000827 -16 
Doc No D -16.394 
 
 
[Chong 2013] Chong Y, Fryar CD, Gu Q. Prescription Sleep Aid Use Among Adults: 
[LOCATION_002], 2005–2010. NCHS Data Brief 2013;127. 
[Citrome
 2014] Ci trome L. Suvorexant for insomnia: a systematic review of the efficacy 
and safety profile for this newly approved hypnotic - what is the
 number needed to 
treat, number needed to harm and likelihood to be helped or harmed? Int J Clin 
Pract 2014;68(12):1429–41.  
[CMS  2008] Cent
ers for Medicare and Medicaid Services. National Coverage 
Determination for Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA). NCD #240.4 2005 [cited in 2008; accessed on 8 June 2016]. A vailable from: 
https://www
.cms.gov/medicare -coverage -
database/in
dexes/national -and-local -indexes.as
px. 
[Dam 2008]
 Dam TT, Ewing S, Ancoli -Israel S
, Ensrud K, Redline S, Stone K. 
Association between sleep and physical function in older men: the MrOS  sleep 
study. J Am Geriatr Soc 2008;56(9):1665–73. 
[de Lecea 1998]
 de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. 
The hypocretins: hypothalamus -specific pe
ptides with neuroexcitatory activity. 
Proc Natl Acad Sci [LOCATION_003] 1998;95:322–7. 
[Desarnaud  2004]
 Desarnaud F, Murillo -Rodriguez
 E, Lin L, Xu M, Gerashchenko D, 
Shiromani SN, et al. The diurnal rhythm of hypocretin in young and old F344 rats. 
Sleep 2004;27:851–6. 
[DSM -5 2013] Americ
an Psychiatric Association (APA). Diagnostic and Statistical 
Manual of Mental Disorders (5th edition): Diagnostic criteria for Primary Insomnia, 2013 [accessed on 8 June 2016]. Available from:  
http://www.psychiatry.org/psychiatrists/practice/dsm/dsm
-5. 
[EMA 2011] European medicines agency, committee for medicinal products for human 
use, guideline on medicinal products for the treatment of insomnia; EMA/CHMP/[ZIP_CODE]/2009 previously (EMEA/[ZIP_CODE]/2009) Rev. 1 [accessed on 8 June 2016]. Ava
ilable from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351.pdf. 
[EMA 2013]. European medicines agency, committee for medicinal products for human 
use, Qualification Opi[INVESTIGATOR_215186] -Mod as an
 efficient statistical methodology for 
model -based desig
n and analysis of Phase II dose finding studies under model 
uncertainty EMA/CHMP/SAWP/757052/2013 [accessed on 8 June 2016]. 
Available from:  
ACT -[ADDRESS_258889] 2016 , page 108/[ADDRESS_258890]  2016 -000827 -16 
Doc No D -16.394 
 
 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedu
ral_guideline/2014/02/WC500161027.pdf. 
[FDA 2007] FDA Requests Label Change for All Sleep Disorder Drug Products 
[accessed on 8 June 2016]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108868.htm. 
[FDA 2013] FDA Drug Safety Communications. Risk of next morning impairment after 
use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpi[INVESTIGATOR_6730] (Ambien
®, Ambien® CR, Edluar, and Zolpi[INVESTIGATOR_215187])  [accessed  on 
8 June 2016]. Available from: 
 http://w ww.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf. 
[Hagan 1999] Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. 
Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci [LOCATION_003] 1999;96:[ZIP_CODE]–6. 
[Herring  2016] H
erring WJ, Connor KM, Ivgy -May N, Sn
yder E, Liu K, Snavely DB, et 
al. Suvorexant in Patients With Insomnia: Results From Two 3 -Month Randomiz
ed 
Controlled Clinical Trials.  Biol Psychiatry 2016;79(2):136–48. 
[Holbrook 2000] Hol
brook AM, Crowther R, Lotter A, Cheng C, King D. Meta -analysis 
of
 benzodiazepi[INVESTIGATOR_215188]. CMAJ 2000;162(2):225–33. 
[ICH 1998] I
nternational Conference on Harmonisation of technical requirements for 
registration of pharmaceuticals for human use. S tatistical principles for clinical 
trials E9  [accessed on 8 June 2016]. Available from:  
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. 
[Kales 1978] Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical 
syndrome. Science 1978;201(4360):1039–41.  
[Kilduff 2000]
 Kilduff TS, Peyron C. The hypocretin/orexin ligand -receptor
 system: 
implications for sleep and sleep disorders. Trends Neurosci 2000;23:359–65. 
[Kuriyam
a 2014] Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of 
insomnia in adults: a systematic review and meta -analysis.
 Sleep Med 
2014;15(4):385–92.  
[Lieberm
an 2007] Lieberman JA. Update on the safety considerations in the management 
of insomnia with hypnotics: incorporating modified -release 
formulations into 
primary care. Prim Care Companion  J Clin Psychiatry 2007;9(1):25–31.  
ACT -[ADDRESS_258891] 2016 , page 109/[ADDRESS_258892]  2016 -000827 -16 
Doc No D -16.394 
 
 
[Lin 1999] Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder 
canine narcolepsy is caused by a mutation in the hypocretin (o rexin) receptor 2 
gene. Cell. 1999;98(3):365–76. 
[Lopez -Torres Hi
dalgo 2012] Lopez -Torres H
idalgo J, Navarro Bravo B, Parraga 
Martinez I, Andres Pretel F, Tellez Lapeira J, Boix Gras C. Understanding 
insomnia in older adults. Int J Geriatr Psychiatry 2012;27(10):1086–93. 
[Lunesta® USPI] Lunesta® (eszopi[INVESTIGATOR_11123]) US Package Insert. [LOCATION_002] Food and 
Drug Administration full prescribing information . Revised 5/2014. 
[McCall 2004] McCall WV. Sleep in the Elderly: Burden, Diagnosis, and Treatment. 
Prim Care Co mpanion J Clin Psychiatry 2004;6(1):9–20. 
[Meoli 2001] M
eoli AL, Casey KR, Clark RW, Coleman JA Jr, Fayle RW, Troell RJ, et 
al. Hypopnea in sleep -disordered b
reathing in adults. Sleep 2001;24(4):469–70. 
[Mets 2010] M
ets MA, Volkerts ER, Olivier B, Verster JC. Effect of hypnotic drugs on 
body balance and standing steadiness. Sleep Med Rev 2010;14(4):259–67.  
[Mignot 2002] Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, 
et al. The role of cerebrospi[INVESTIGATOR_215189] s. Arch Neurol 2002;59(10):1553–62. 
[Morin 1993] Mor
in CM, Kowatch RA, Barry T, Walton E. Cognitive -behavior the
rapy 
for late -life insom
nia. J Consult Clin Psychol 1993;61(1):137–46.  
[Mort 2000] Mor
t JR, Aparasu RR. Prescribing potentially inappropriate psychotropic 
medications to the ambulatory elderly. Arch Intern Med 2000;160:2825–31 
[Neubauer 2014] Neubauer DN. New and emerging pharmacotherapeutic approaches for 
insomnia. International Review of Psychiatry 2014;26(2):214–24. 
[Nutt 2006] Nutt D. GABAA receptors: subtypes, regional distribution, and function. J 
Clin Sleep Med 2006;2(2):Suppl S7–11.  
[Ohayon 2001] Ohayon MM, Zulley J, Guilleminault C, Smirne  S, Priest RG. How age 
and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc 2001;49(4):360–6. 
[Ohayon 2002] Ohayon MM, Smirne S. Prevalence and consequences of insomnia 
disorders in the general population of Italy. Sleep Med 2002;3(2):115–20. 
[Ohayon 2004] Oha
yon MM, Carskadon MA, Guilleminault C, Vitiello MV. 
Meta -analysi
s of quantitative sleep parameters from childhood to old age in healthy 
ACT -[ADDRESS_258893] 2016 , page 110/[ADDRESS_258894]  2016 -000827 -16 
Doc No D -16.394 
 
 
individuals: developi[INVESTIGATOR_215190]. Sleep 
2004;27(7):1255–73. 
[Ohayon 2005] Ohayon MM, Vecchierini MF. Normative sleep data, cognitive function 
and daily living activities in older adults in the community. Sleep2005;28(8):  
981–9. 
[Ohayon 2009] Oha
yon MM, Reynolds C F. Epi[INVESTIGATOR_215191] -IV and the I
nternational 
Classification of Sleep Disorders (ICSD). Sleep Med 2009;10(9):952–60. 
[Ohayon 2010] Oha
yon MM, Sagales T. Prevalence of insomnia and s leep characteristics 
in the general population of Spain. Sleep Med 2010;11(10):1010–8. 
[Petursson 1981] Petursson H, Lader MH. Benzodiazepi[INVESTIGATOR_215192]. Br J Addict 
1981;76(2):133–45. 
[Pi[INVESTIGATOR_42849] 2007] Pi[INVESTIGATOR_42882], Crabtree VM, Scherer MR. The future of behavioral sleep 
medicine. J Clin Sleep Med. 2007;3(1):73–9. 
[Pi[INVESTIGATOR_17872] 2006]
 Pi[INVESTIGATOR_17872] J, Bornkamp B, Bretz F. Design and analysis of dose -finding 
studi
es combining multiple comparisons and modeling procedures. J Biopharm 
Stat. 2006;16(5):639–56. 
[Pi[INVESTIGATOR_17872] 2014
] Pi[INVESTIGATOR_17872] J, Bornkamp B, Glimm E, Bretz F. Model -based dose fi
nding 
under model uncertainty using general parametric models. Statistics in Medicine 
2014;33(10):1646–61 
[Posner 2007] P
osner K. Suicidality issues in clinical trials: Columbia suicidal adverse 
event identification in FDA safety analyses. Division of Metabolism and Endocrinology Products Advisory Committee Meeting 2007 [accessed on 10 June 
2016]. Available from: 
www.fda.
gov/ohrms/dockets/ac/07/slides/2007 -4306s1 -01-
CU-Posner.ppt . 
[Praplan -Pahud 1990] Prapl
an-Pahud J, Forst
er A, Gamulin Z, Tassonyi E, Sauvanet JP. 
Preoperative sedation before regional anaesthesia: comparison between zolpi[INVESTIGATOR_6730], midazolam and placebo. Br J Anaesth 1990;64(6):670–4. 
[Sakurai  2007]
 Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep 
and wakefulness. Nat Rev Neurosci 2007;8:171–81. 
[Samson 2010] Samson WK, Bagley SL, Ferguson AV, White MM. Orexin receptor 
subtype activation and locomotor behaviour in the rat. A cta Physiol (Oxf) 
2010;198:313–24. 
ACT -[ADDRESS_258895] 2016 , page 111/[ADDRESS_258896]  2016 -000827 -16 
Doc No D -16.394 
 
 
[Scharf 2007] Scharf MB, Black J, Hull S, Landin R, Farber R. Long -term nightly  
treatment with indiplon in adults with primary insomnia: results of a double -blind, 
placebo -controlled, 3 -month study
. Sleep 2007;30(6):743–52.  
[Scharf 2008]
 Scharf M, Rogowski R, Hull S, Cohn M, Mayleben D, Feldman N, et al. 
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with 
primary insomnia: a randomized, double -blind, placebo -controlled c
rossover study. 
J Clin Psychiatry. 2008;69(10):1557–64.  
[Schlack 2013]
 Schlack R, Hapke U, Maske U, Busch M, Cohrs S. Frequency and 
distribution of sleep problems and insomnia in the adult population in [LOCATION_013]: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundhe itsschutz 
2013;56(5
-6):740–8. 
[Schutte -Rodin 2008] Schut
te-Rodin S, Broch 
L, Buysse D, Dorsey C, Sateia M. Clinical 
guideline for the evaluation and management of chronic insomnia in adults. J Clin 
Sleep Med 2008;4(5):487–504. 
[Sheehan 1996] S
heehan DV, Ha rnett-Sheehan K,
 Raj BA. The measurement of 
disability. Int Clin Psychopharmacol 1996;[ADDRESS_258897] 3:S89 -95. 
[Simpson 2008] S
impson D, Curran MP. Ramelteon: a review of its use in insomnia. 
Drugs 2008;68(13):1901–19. 
[Thannickal 2000] Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, 
Aldrich M, et al. Reduced number of hypocretin neurons in human nar colepsy. 
Neuron. 2000;27(3):469–74. 
[Treat  Guidel 
Med Lett 2009] Drugs for insomnia. Trea t Guidel Med Lett 
2009;7(79):23 -26. 
[Vermeeren 2
015] Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van 
Oers AC, et al. On -the-Road Driving
 Performance the Morning after Bedtime Use 
of Suvorexant 20 and 40 mg: A Study in Non -Elderly H
ealthy Volunteers. Sleep 
2015;38(11):1803–13. 
[Zeitze
r 2003] Zeitzer JM, B uckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E . 
Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003;23:3555–60. 
ACT -[ADDRESS_258898] 2016 , page 113/[ADDRESS_258899]  2016 -000827 -16 
Doc No D -16.394 
 
 
Protime  M/F seconds  9.4 13 9.3 13.1 NA NA NA 100.1  seconds  9.4 13 9.3 13.1 NA NA NA 100.1  
INR  M/F N/A 0.8 1.2 0.79 1.21 NA NA NA 5 N/A 0.8 1.2 0.79 1.21 NA NA NA 5 
INR = International Normalized Ratio; M/F = male/female; N/A = not applicable.  
  
ACT -[ADDRESS_258900] 2016 , page 115/[ADDRESS_258901]  2016 -000827 -16 
Doc No D -16.394 
 
 
Triglycerides  M/F mg/dL  0 149 NA 150 NA NA NA NA mmol/L  0.00 1.68 NA 1.69 NA NA NA NA 
Uric acid  F mg/dL  2.3 6.6 2.2 6.7 NA 13.1 NA NA umol/L  137 393 136 394 NA 780 NA NA 
TSH  M/F µIU/mL  0.35 5.50 0.34 5.51 NA NA NA NA mIU/L  0.35 5.50 0.34 5.51 NA NA NA NA 
Triiodothyronine, Free (FT3)  M/F pg/mL  2.3 4.2 2.2 4.3 NA NA NA NA pmol/L  3.5 6.5 3.4 6.6 NA NA NA NA 
Thyroxine, Total (T4)  M/F µg/dL  4.5 10.9 4.4 11.0 NA NA NA NA nmol/L  58 141 57 142 NA NA NA NA 
M/F = male/female; NA = n ot applicable; TSH = thyroid -stimulati ng hormone.  
 
ACT -[ADDRESS_258902] 2016 , page 116/[ADDRESS_258903] the center.  
On non -PSG nigh
ts, the subjects will be instructed to limit alcohol to a maximum of 
2 drinks per day. 
A drink is def
ined as: 
• A bottle/can of 33 cl/12 ounces of beer ( ≈14 grams alcohol) 
• A glass of 10 –12 cl/4 ounces of wine (≈12 grams alcohol)  
• A small glass  of 3–4 cl/1 ounce of liquor (≈9 grams alcohol)  
  
ACT -[ADDRESS_258904] 2016 , page 117/[ADDRESS_258905]  2016 -000827 -16 
Doc No D -16.394 
 
 
Appendix 3  Caffeine content  of common beverages 
The content of caffeine in  common caffeine beverages is approximately:  
• A standar
d cup of brewed or restaurant -style  coffee 
contains approximately  
150–200 mg caffeine.  
• A can of mos
t soda drinks (unless decaffeinated soda drinks) contains approximately 
50 mg caffeine.  
• A can of energy drinks contains approximately 150–[ADDRESS_258906] 2016 , page 118/[ADDRESS_258907]  2016 -000827 -16 
Doc No D -16.394 
 
 
Appendix  4  Forbidden and restricted concomitant medications  
1. Forbidden (F) or restricted (R) concomitant medications due to CNS side effects. 
 To be eligi
ble, subjec ts must not be treated with CNS -active drug
s for 5 half- lives of 
the respective drug (but at least 2 weeks) prior to V1 . The use of CNS -active 
drugs
 is forbidden or restricted until 24 hours after EOT (V7).  
Drug Class  Examples  Forbidden / 
Restricted  Comment  
Centrally Acting 
Anticholinergics 
and 
Antihistamines  OTC Hista mine1 -Antihist amines, e.g.:  
 Diphenhydra
mine HCl,  
Carbinoxamine,  
Dimenhydrinate ,  
Triprolidine HCl Hydroxizine  F  
Antihistamines  Sedating  
Non-sedating (loratidine, fexofenadine)  F 
R Non-sedating 
antihistamines may be 
used maximum twice 
weekly for allergic 
symptoms.  
Psychotropi[INVESTIGATOR_42884]:  
Amphetamines  
Modafinil, armodafinil  
Methylphenidate  F  
 Antidepressants  F  
 Antipsychotics, including depot 
neuroleptics  F  
 Anxiolytics, e.g.:  
Lorazepam  
Alprazolam  
Buspi[INVESTIGATOR_5331]  F  
 Sleep medications, e.g.: 
Prescribed zolpi[INVESTIGATOR_215193], suvorexant, ramelteon and 
OTC  F  
 MAOIs  F  
 Melatonin  F  
 Mood stabilizers, e.g.:  
Lamotrigine  
Gabapentin  
Lithium  
Oxcarbazepi[INVESTIGATOR_215194]  F  
ACT -[ADDRESS_258908] 2016 , page 119/[ADDRESS_258909] be avoided if 
there are effective 
alternative medications 
(such as NSAI Ds) 
 Centrally acting muscle relaxants with 
psychotropic effects e.g.,  
Methocarbamol  R Use of centrally acting 
muscle relaxants must be 
avoided if there are 
effective alternative medications (such as 
NSAI Ds) 
 Herbal preparations with possible psychotropic effects, e.g., St Johns 
Wort, valerian  F  
 Tryptophan  F  
Anticonvulsants  Barbiturates  
Benzodiazepi[INVESTIGATOR_215195] (e.g, lamotrigine)  
Succinimides (e.g., Ethosuximide)  F  
Other  Warfarin, Heparin, Ticlopi[INVESTIGATOR_5325]  F  
 Isotrenitoin  F  
 Systemic glucocorticoids  F  
 Diet Pi[INVESTIGATOR_3353] (prescription and OTC)  F  
 Pseudoephedrine  R May only be used before 
14.00 , and no more than 
twice a week. Dosage is limited to 30 mg of active ingredient in each tablet. 
Extended release 
formulations are 
forbidden.  
GABA = gamma -aminobutyric acid; MAOI = monoamine oxidase inhibitor; NSAID = nonsteroidal anti -inflamm atory 
drug; OTC = over -the-counter.  
 
2. Non-exhaustive
 list of forbidden concomitant medications and diets due to potential 
drug interactions with CYP3A4 ( moderate and strong inhibitors , inducers and 
sensitive substrates ), with P -gP substra
tes, with BCRP substrates, and with CYP2B6 
substrates . 
ACT -[ADDRESS_258910] 2016 , page 120/[ADDRESS_258911] be discontinued no later than 1 week  prior to V1  and are 
forbidden until 24 hours after EOT (V6).  
CYP3A4 moderate and strong inhibitors and CYP3A4 inducers: 
Inhibitors of CYP3A4  Inducers of CYP3A4  
HIV antivirals: atazanavir, boceprevir, cobicistat, 
darunavir, delaviridine, fosamprenavir, 
indinavir, lopi[INVESTIGATOR_054], nelfinavir, ritonavir , 
saquinavir, telaprevir  HIV antivirals: efavirenz, etravirine, nevirapi[INVESTIGATOR_215196]: ciprofloxacin, clarithromycin, 
erythromycin, norfloxacin, quinupristin, 
telithromycin, troleandomycin,  Antibiotics: nafcillin, rifabutin, rifampin  
Antifungal: fluconazole, itraconazole, ketoconazole, 
posaconazole, voriconazole  
CNS -active: fluvoxamine, nefazodone  CNS -active: carbamazepi[INVESTIGATOR_050], fenobarbital, 
modafinil, phenytion, St John’ s Wort  
Cardiovascular: amiodarone, diltiazem, 
dronedarone, mibefradil, verapamil   Cardiovascular: bosentan  
 Hypoglycemics: p ioglitazone, troglitazone  
Aprepi[INVESTIGATOR_053], conivaptant, c imetidine , imatinib   
Grapefruit and grapefruit  juice   
CYP3A4 substrates: alfentanil, api[INVESTIGATOR_3822], budesonide, buspi[INVESTIGATOR_5331], cisapride, crizotinib, 
cyclosporine, darifenacin, dihydroergotamine, domperidone, dronedarone, erlotinib, ergotamine, ethinylestradiol, erythromycin, felodipi[INVESTIGATOR_050], fentanyl, halofantrine, ketamine, lovastatin, lurasidone, maraviroc, midazolam, nifedipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], oxycodone, quetiapi[INVESTIGATOR_050], saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, terfenadine, ticagrelor, tipranavir/ritonavir, tolvaptan, triazolam, vardenafil, verapami l. 
P-gP substra
tes: aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, 
everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan.  
BCRP  substra
tes: imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, 
rosuvastatin, sulfasalazine, topotecan. 
CYP2B6 substrates: bupropi[INVESTIGATOR_2394], cyclophosphamide, efavirenz, irinotecan, ketamine, 
promethazine, propofol, selegiline, valproic acid. 
 
ACT -[ADDRESS_258912] 2016 , page 121/[ADDRESS_258913] 

ACT -[ADDRESS_258914] 2016 , page 122/[ADDRESS_258915]  2016 -000827 -16 
Doc No D -16.394 
 
 
Appendix 6  Insomnia Severity Index 

ACT -[ADDRESS_258916] 2016 , page 123/[ADDRESS_258917]  2016 -000827 -16 
Doc No D -16.394 
 
 
Appendix 7  Sheehan Disability Scale 

ACT -[ADDRESS_258918] 2016 , page 124/[ADDRESS_258919] 2016 , page 125/[ADDRESS_258920] 2016 , page 126/[ADDRESS_258921] 2016 , page 127/[ADDRESS_258922] of each sleep stage ( S1, S2, SWS and REM) 
for the whole night, and for each quarter of the night.  Exploratory  
Sleep stages latency  Meane latency to each sleep stage ( S1, S2 , SWS, and REM).  
Sleep continuity  Shifts between sleep 
stages  Meane number and frequency of shifts from S2, SWS or REM  to S1 or wake for the 
whole night.  
Exploratory  Wake time during 
sleep  Meane wake time during sleep: time spent in epochs scored as wake between LPS and 
last epoch not scored wake for the whole night.  
Awakenings  Meane frequency of awakenings: number of awakenings between first epoch and last 
epoch not scored wake for the whole night, by [CONTACT_215261].  
sNA Absolute Change from Baselinec to Days [ADDRESS_258923] 2016 , page 128/[ADDRESS_258924]  2016 -000827 -16 
Doc No D -16.394 
 
 
Next -day 
performance  VAS  Absolute change from Baselinec to Days 1 and 2d Exploratory  
Note: a ‘Baseline’ is the mean of the two  PSG nights during run -in period ( V2), b ‘Days 1 and 2’ is the mean of the corresponding two PSG treatment nights for  a given 
treatment period,  c ‘Baseline’ is the mean value of the sleep d iary entries  during run -in period (
V2), d ‘Days 1 and 2’ is the mean value of the corresponding sleep 
diary entries for a given treatment period, e ‘M ean’ calculated based on two  PSG nights value for a given  treatment period.  
LPS = latency
 to persistent sleep; PSG = polysomnography; REM = rapid eye movement; SE = sleep efficiency; sLSO = subjective latency to sleep onset; sNA = self -
reported 
number of awakenings; sTST = subjective total sleep time; SWS = slow -wave sleep; T
ST = total sleep time; VAS = visual analog scale; WASO = wake 
after sleep onset.   